View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Aug. 31, 2013	Nov. 25, 2013	Feb. 28, 2013
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Aug. 31, 2013
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	0001176309
Current Fiscal Year End Date	--08-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2013
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 52,694,028
Entity Common Stock, Shares Outstanding		7,947,872

CONSOLIDATED BALANCE SHEETS - USD ($)	Aug. 31, 2013	Aug. 31, 2012
CURRENT ASSETS:
Cash and cash equivalents	$ 2,272,228	$ 4,430,740
Short term deposits (note 2)	5,246,627	454,381
Marketable securities (note 3)	956,376	200,311
Restricted cash (note 1o)	16,000	16,000
Prepaid expenses and other current assets (note 4)	90,103	89,998
Related parties (note 16)	4,530	404
Grants receivable from the chief scientist	58,412	84,642
T o t a l current assets	8,644,276	5,276,476
LONG TERM DEPOSITS AND INVESTMENT (note 8b)	4,593	8,867
AMOUNTS FUNDED IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT (note 7)	5,545	4,740
PROPERTY AND EQUIPMENT, net (note 5)	5,768	4,768
T o t a l assets	8,660,182	5,294,851
CURRENT LIABILITIES:
Accounts payable and accrued expenses (note 11)	450,941	597,173
Account payable with former shareholder	47,252	47,252
T o t a l current liabilities	498,193	644,425
LONG TERM LIABILITIES:
Warrants (notes 6)		637,182
Employee rights upon retirement (note 7)	8,004	6,959
Provision for uncertain tax position (note 15e)	23,210	228,272
Total long term liabilities	31,214	872,413
COMMITMENTS (note 8)
STOCKHOLDERS' EQUITY:
Common stock, shares issued	95,238	80,075
Accumulated other comprehensive income	303,403
Additional paid-in capital	29,855,723	21,589,715
Deficit accumulated during the development stage	(22,123,589)	(17,891,777)
T o t a l stockholders' equity	8,130,775	3,778,013
T o t a l liabilities and stockholders' equity	$ 8,660,182	$ 5,294,851

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares	Aug. 31, 2013	Aug. 31, 2012
CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]
Common stock, par value per share	$ 0.012	$ 0.012
Common stock, shares authorized	16,666,667	16,666,667
Common stock, shares issued	7,937,872	6,674,068
Common stock, shares outstanding	7,937,872	6,674,068

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended		137 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
CONDENSED CONSOLIDATED STATEMENTS OF OPERATION [Abstract]
RESEARCH AND DEVELOPMENT EXPENSES, NET (note 12)	$ 2,271,794	$ 1,680,845	$ 11,804,488
IMPAIRMENT OF INVESTMENT			434,876
GENERAL AND ADMINISTRATIVE EXPENSES (note 13)	2,032,129	1,203,164	10,193,676
OPERATING LOSS	4,303,923	2,884,009	22,433,040
FINANCIAL INCOME (note 15a)	(180,495)	(13,126)	(387,653)
GAIN ON SALE OF INVESTMENT			(1,033,004)
IMPAIRMENT OF AVAILABLE- FOR-SALE SECURITIES		184,254	381,666
FINANCIAL EXPENSE (note 15b)	313,446	199,123	693,826
LOSS BEFORE TAXES ON INCOME	4,436,874	3,254,260	22,087,875
TAXES ON INCOME (note 16)	(205,062)	90,218	35,714
NET LOSS FOR THE PERIOD	4,231,812	3,344,478	22,123,589
OTHER COMPREHENSIVE INCOME, NET OF TAX
SUBSEQUENT INCREASE IN THE FAIR VALUE OF AVAILABLE FOR SALE SECURITIES PREVIOUSLY WRITTEN DOWN AS IMPAIRED	(130,845)		(130,845)
RECLASSIFICATION ADJUSTMENT FOR GAINS INCLUDED IN NET LOSS	90,370		90,370
UNREALIZED GAIN ON AVAILABLE FOR SALE SECURITIES	(262,928)		(262,928)
TOTAL OTHER COMPREHENSIVE INCOME	(303,403)		(303,403)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$ 3,928,409	$ 3,344,478	$ 21,820,186
BASIC AND DILUTED LOSS PER COMMON SHARE	$ (0.59)	$ (0.57)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON STOCK	7,209,283	5,884,595

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock [Member]	Additional paid-in capital [Member]	Other Comprehensive Income [Member]	Deficit accumulated during the development stage [Member]
BALANCE at Aug. 31, 2007	$ 513,131	$ 45,231	$ 4,946,833		$ (4,478,933)
BALANCE, shares at Aug. 31, 2007		3,769,967
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	5,784,800	$ 10,178	5,774,622
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares		848,288
SHARES ISSUED FOR SERVICES	116,110	$ 293	115,817
SHARES ISSUED FOR SERVICES, shares		24,419
SHARES ISSUED FOR CONVERSION OF CONVERTIBLE NOTE	275,000	$ 550	274,450
SHARES ISSUED FOR CONVERSION OF CONVERTIBLE NOTE, shares		45,844
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	459,467		459,467
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	203,982		203,982
IMPUTED INTEREST	3,780		3,780
NET LOSS	(2,769,271)				(2,769,271)
BALANCE at Aug. 31, 2008	4,593,060	$ 56,252	11,785,012		(7,248,204)
BALANCE, shares at Aug. 31, 2008		4,688,518
SHARES ISSUED FOR SERVICES	152,928	$ 204	152,724
SHARES ISSUED FOR SERVICES, shares		17,012
SHARES TO BE ISSUED FOR SERVICES RENDERED	203,699		203,699
SHARES TO BE ISSUED FOR SERVICES RENDERED, shares
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	436,025		436,025
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	117,174		117,174
IMPUTED INTEREST	3,780		3,780
NET LOSS	(2,760,474)				(2,760,474)
BALANCE at Aug. 31, 2009	2,746,192	$ 56,456	12,698,414		(10,008,678)
BALANCE, shares at Aug. 31, 2009		4,705,530
SHARES ISSUED FOR SERVICES	249,850	$ 1,109	248,741
SHARES ISSUED FOR SERVICES, shares		92,416
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	690,882		690,882
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	116,944		116,944
IMPUTED INTEREST	3,780		3,780
NET LOSS	(2,977,376)				(2,977,376)
BALANCE at Aug. 31, 2010	830,272	$ 57,565	13,758,761		(12,986,054)
BALANCE, shares at Aug. 31, 2010		4,797,946
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	3,694,212	$ 11,808	3,682,404
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares		984,209
SHARES ISSUED FOR SERVICES	227,569	$ 731	226,838
SHARES ISSUED FOR SERVICES, shares		60,887
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	502,593		502,593
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	26,733		26,733
IMPUTED INTEREST	3,782		3,782
NET LOSS	(1,561,245)				(1,561,245)
BALANCE at Aug. 31, 2011	3,723,916	$ 70,104	18,201,111		(14,547,299)
BALANCE, shares at Aug. 31, 2011		5,843,042
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	2,944,464	$ 9,622	2,984,842
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares		801,942
SHARES AND WARRANTS TO BE ISSUED FOR CASH	25,093		25,093
SHARES ISSUED FOR SERVICES	107,860	$ 349	107,511
SHARES ISSUED FOR SERVICES, shares		29,084
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	200,866		200,866
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	70,292		70,292
NET LOSS	(3,344,478)				(3,344,478)
BALANCE at Aug. 31, 2012	$ 3,778,013	$ 80,075	21,589,715		(17,891,777)
BALANCE, shares at Aug. 31, 2012	6,674,068	6,674,068
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES	$ 1,422,592	$ 4,192	1,418,400
SHARES AND WARRANTS ISSUED FOR CASH- NET OF ISSUANCE EXPENSES, shares		349,396
SHARES ISSUED FOR CASH, NET	4,238,889	$ 7,897	4,230,992
SHARES ISSUED FOR CASH, NET, shares		658,144
SHARES TO BE ISSUED FOR SERVICES RENDERED	244,457	$ 404	244,053
SHARES TO BE ISSUED FOR SERVICES RENDERED, shares		33,709
SHARES ISSUED FOR MARKETABLE SECURITIES	628,630	$ 2,390	626,240
SHARES ISSUED FOR MARKETABLE SECURITIES, shares		199,172
EXCHANGE OF WARRANTS (see note 5)	917,809		917,809
EXERCISE OF WARRANTS	109,575	$ 280	109,295
EXERCISE OF WARRANTS, shares		23,383
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO EMPLOYEES AND DIRECTORS	562,966		562,966
STOCK BASED COMPENSATION RELATED TO OPTIONS GRANTED TO CONSULTANTS	156,253		156,253
OTHER COMPREHENSIVE INCOME (LOSS)	303,403			303,403
NET LOSS	(4,231,812)				(4,231,812)
BALANCE at Aug. 31, 2013	$ 8,130,775	$ 95,238	$ 29,855,723	$ 303,403	$ (22,123,589)
BALANCE, shares at Aug. 31, 2013	7,937,872	7,937,872

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended		137 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,231,812)	$ (3,344,478)	$ (22,123,589)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,379	14,737	126,223
Amortization of debt discount			108,000
Exchange differences	19,179	62,494	50,216
Stock based compensation	719,219	271,158	5,690,506
Common stock issued for services	244,457	107,860	1,400,413
Gain on sale of investment	(50,703)		(1,083,707)
Impairment of investments			434,876
Impairment of available for sale securities		184,254	381,666
Imputed interest			23,559
Exchange of warrants	296,982		296,982
Changes in fair value of warrant liabilities	(44,699)	142,704	98,005
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(3,094)	(31,199)	(163,253)
Restricted cash			(16,000)
Accounts payable and accrued expenses	(146,232)	203,133	450,941
Liability of employee rights upon retirement	1,045	(2,489)	21,231
Provision for uncertain tax position	(205,062)	90,218	23,210
Total net cash used in operating activities	(3,395,341)	(2,301,608)	(14,280,721)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(6,379)	(2,129)	(131,991)
Purchase of short term deposits	(5,846,628)	(475,353)	(11,750,363)
Proceeds from sale of short term deposits	1,054,011	1,800,000	6,482,011
Proceeds from sale of investment and marketable securities	226,671	450,000	676,671
Funds in respect of employee rights upon retirement	(2,090)	(3,620)	(8,985)
Lease deposits	4,894		(2,615)
Total net cash provided by (used in) investing activities	(4,569,521)	1,768,898	(4,735,272)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants - net of issuance expenses	5,714,918	3,488,942	20,859,553
Proceeds from exercise of warrants and options	109,575		109,575
Receipts on account of shares issuances			6,061
Proceeds from convertible notes			275,000
Proceeds from short term note payable			120,000
Payments of short term note payable			(120,000)
Shareholder advances			66,243
Net cash provided by financing activities	5,824,493	3,488,942	21,316,432
EFFECT OF EXCHANGE RATE CHANGES ON CASH	(18,143)	(38,857)	(28,211)
INCREASE IN CASH AND CASH EQUIVALENTS	(2,158,512)	2,917,375	2,272,228
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	4,430,740	1,513,365
CASH AND CASH EQUIVALENTS AT END OF PERIOD	2,272,228	4,430,740	2,272,228
Material non cash investing and financing activities:
Discount on convertible note related to beneficial conversion feature			108,000
Shares and warrants issued for offering costs			77,779
Contribution to paid in capital			18,991
Exchange of warrants	917,809		917,809
Shares and warrants issued for marketable securities	628,630		628,630
Shares and warrants to be issued for cash		$ 25,093

SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Aug. 31, 2013

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

General

Incorporation and operations

Oramed Pharmaceuticals Inc. (the "Company") was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd ("Hadasit") to acquire the provisional patent related to orally ingestible insulin pill to be used for the treatment of individuals with diabetes. In subsequent periods, the Company entered into additional development agreements with Hadasit, the most recent of which was signed on September 11, 2011, see also note 8a.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd., which is engaged in research and development. Unless the context indicates otherwise, the term "Group" refers to Oramed Pharmaceuticals Inc. and its Israeli subsidiary, Oramed Ltd. (the "Subsidiary"), (together with the Company, "the Group").

In March 2011, the Subsidiary sold shares of its investee company, Entera Bio Ltd ("Entera") to D.N.A Biomedical Solutions Ltd ("D.N.A"), remaining a 3% interest, which is accounted for as a cost method investment (amounting $1,027). In consideration for the shares sold to D.N.A, the Company received a promissory note issued by D.N.A in the principal amount of $450,000, with an annual interest rate of 0.45%, that was paid in full in November 2011, and 8,404,667 ordinary shares of D.N.A, see also note 3.

As part of this agreement, the Subsidiary entered into a patent transfer agreement according to which, the Subsidiary assigned to Entera all of its right, title and interest in and to the patent application that it has licensed to Entera since August 2010. Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera's net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. As of August 31, 2013, Entera had not yet realized any revenues and had not paid any royalties to the Subsidiary.

Development and liquidity risks

The Company has been in the development stage since its formation and has not yet generated any revenues from its operations.

The Group is engaged in research and development in the biotechnology field and is considered a development stage company in accordance with the ASC Topic 915 "Development Stage Entities" due to the fact that it has not generated any revenues from its operations.

Successful completion of the Company's development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the FDA prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company's ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.

Based on its current cash resources and commitments, and cash received in private and public offerings in the year ended August 31, 2013, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months and beyond, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.

Reverse stock split

On January 10, 2013, the Company's Board of Directors approved a reverse stock split at a ratio of one-for-twelve, effective January 22, 2013, which decreased the number of common shares issued and outstanding as of January 23, 2013, from approximately 86.5 million shares to approximately 7.2 million shares and the number of authorized common shares from 200 million shares to approximately 16.7 million shares. All share and per share amounts included in the consolidated financial statements have been adjusted retroactively to reflect the effects of the reverse stock split.

Accounting principles

The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP").

Use of estimates in the preparation of financial statements

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates.

As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock based compensation, valuation and impairment of marketable securities and valuation of tax exposures.

Functional currency

The currency of the primary economic environment in which the operations of the Group are conducted is the U.S. dollar ("$" or "dollar"). Therefore, the functional currency of the Group is the dollar.

Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions - exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate.

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation.

Property and equipment

Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the assets.

Annual rates of depreciation are as follows:

	%
Computers and peripheral equipment		33
Office furniture and equipment		15-33

Leasehold improvements are amortized over the term of the lease which is shorter than the estimated useful life of the improvements.

Income taxes

1. Deferred taxes

Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets.

Regarding the Subsidiary, the recognition is prohibited for deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities.

Taxes that would apply in the event of disposal of investments in the subsidiary have not been taken into account in computing deferred taxes, as it is the Company's intention to hold this investment, not to realize it.

2. Uncertainty in income tax

The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company's policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses.

Research and development, net

Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, costs of registered patents materials, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company's clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred.

Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company out sources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately.

Grants received from the OCS and Bio-Jerusalem are recognized as grant income when the grants become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grants are deducted from the related research and development expenses as the costs are incurred and are presented in R&D expenses, net. See also notes 8(k) and 8(l).

Cash equivalents

The Company considers all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.

Loss per common share

Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding and shares relating to receipts on account of shares in equity during the period. Outstanding stock options and warrants have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stock options and warrants excluded from the calculation of diluted net loss was 2,343,972 for the year ended August 31, 2013 (1,892,180 for the year ended August 31, 2012). The computation of basic and diluted net loss per common share was adjusted retroactively for all periods presented to reflect the Company's reverse stock split. See also note 1a(3).

Impairment in value of long-lived assets

The Company reviews long-lived assets, to be held and used, for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. In the event the sum of the expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment loss would be recognized, and the assets are written down to their estimated fair values

Stock based compensation

Equity awards granted to employees are accounted for using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimated forfeitures based on historical experience and anticipated future conditions.

The Company elected to recognize compensation cost for an award with only service conditions that has a graded vesting schedule using the accelerated method based on the multiple-option award approach. When stock options are granted as consideration for services provided by consultants and other non-employees, the transaction is accounted for based on the fair value of the consideration received or the fair value of the stock options issued, whichever is more reliably measurable. The fair value of the options granted is measured on a final basis at the end of the related service period and is recognized over the related service period using the straight-line method.

Warrants issued as part of capital raisings that are classified as a liability

Warrants that entitle the holder to down-round protection (through ratchet and anti-dilution provisions) are classified as liabilities in the statement of financial position.

The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net. See note 6.

Fair value measurement:

Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

Level 1:

Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2:

Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3:

Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of August 31, 2013 the assets or liabilities measured at fair value comprise of available for sale securities (level 1).

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent.

In order to secure the fulfillment of the Company's obligations under the derivatives agreements, the Company has placed a restricted deposit with the bank in an amount of $16,000.

Available-for-sale securities are reported at fair value, with unrealized gains and losses, net of related tax recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.

The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and the Company's ability and intent to hold the investment. Realized gains and losses on sales of the securities are included in the consolidated statement of operations as financial income or expenses.

Concentration of credit risks

Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, deposit and short term investments which are deposited in major financial institutions. The Company is of the opinion that the credit risk in respect of these balances is remote.

Newly issued and recently adopted accounting pronouncements:

In June 2011, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update (ASU) 2011-05, an update to ASC No. 220, "Presentation of Comprehensive Income," which eliminates the option to present other comprehensive income and its components in the statement of shareholders' equity. The Company can elect to present the items of net income and other comprehensive income in a single continuous statement of comprehensive income or in two separate, but consecutive, statements. Under either method the statement would need to be presented with equal prominence as the other primary financial statements. The amended guidance, which must be applied retroactively, is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, with earlier adoption permitted. In December 2011, the FASB issued another update on the topic, which deferred the effective date pertaining only to the presentation of reclassification adjustments on the face of the financial statements. The Company adopted the pronouncement in the first quarter of fiscal year 2013.

In February 2013, the FASB issued ASU 2013-02, Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income ("ASU 2013-02"). This update requires an entity to provide information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, ASU 2013-02 requires presentation, either on the face of the income statement or in the notes, of significant amounts reclassified out of accumulated other comprehensive income by respective line items of net income, but only if the amounts reclassified are required to be reclassified in their entirety in the same reporting period. For amounts that are not required to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures that provide additional details about these amounts. The amendments in ASU 2013-02 will be effective prospectively for annual reporting periods beginning after December 15, 2012, and interim periods within those annual periods. The accounting update will be applicable to the Company beginning in the first quarter of fiscal year 2014. The Company does not expect the adoption of ASU 2013-02 to have a material effect on the consolidated financial statement presentation.

In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (ASU 2013-11). This update requires an entity to present in the financial statements an unrecognized tax benefit, or a portion of an unrecognized tax benefit, as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carryforward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The assessment of whether a deferred tax asset is available is based on the unrecognized tax benefit and deferred tax asset that exist at the reporting date and should be made presuming disallowance of the tax position at the reporting date. The amendments in ASU 2013-11 will be effective prospectively for annual reporting periods beginning after December 15, 2013, and interim periods within those annual periods. The accounting update will be applicable to the Company beginning in the first quarter of fiscal year 2015. The Company does not expect the adoption of ASU 2013-11 to have a material effect on the consolidated financial statement presentation.

SHORT TERM INVESTMENTS

12 Months Ended

Aug. 31, 2013

SHORT TERM INVESTMENTS [Abstract]

SHORT TERM INVESTMENTS

NOTE 2 - SHORT TERM DEPOSITS:

Amounts that represent bank deposits that do not meet the cash equivalent criteria are the following:

	August 31
	2013				2012
	Annual interest rate		Amount		Annual interest rate		Amount
Dollar deposits		0.6-1.06%	$	5,111,914		0.85%	$	260,371
NIS deposits		1.93%		134,713		1.93-1.97%		194,010
			$	5,246,627			$	454,381

MARKETABLE SECURITIES

12 Months Ended

Aug. 31, 2013

MARKETABLE SECURITIES [Abstract]

MARKETABLE SECURITIES

NOTE 3 - MARKETABLE SECURITIES:

During the reporting period, marketable securities consist wholly of equity securities of D.N.A, which were received in March 2011 as part of the consideration for selling the shares of Entera, see also note 1a(1), and in October 2012, as an option to purchase ordinary shares of D.N.A with no additional costs in exchange for the Company's common stock (the "D.N.A Option"), see also note 9e. The D.N.A Option was exercised by the Company in February 2013 for 21,637,611 shares of D.N.A. Pursuant to Tel Aviv Stock Exchange ("TASE") policy regarding private placements, trading of such shares was restricted until August 2013. Until August 26, 2013, the fair value of the restricted securities was measured based on the quoted prices of the otherwise identical unrestricted securities, adjusted for the effect of the restriction by applying a proper discount. The discount was determined with reference to other similar restricted instruments. Similar securities, with no restriction on tradability, are quoted on an active market.

As of August 31, 2013 the securities were reclassified to level 1, since the restriction period was over. Those securities are classified as available-for-sale and are recorded at fair value.

On February 14, 2013 the Subsidiary sold 3,500,000 of the D.N.A shares in a private transaction for a total of NIS 420,000 (or approximately $114,130). On March 5, 2013 each of the Subsidiary and the Company sold additional 1,750,000 of their D.N.A shares in a private transaction for a total of NIS 420,000 (or approximately $112,540).

The cost of the securities sold and the amount reclassified out of accumulated other comprehensive income into net loss, were determined by specific identification.

The shares are traded on the TASE and have a quoted price. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.

Financial assets carried at fair value as of August 31, 2013 and 2012 are classified as level 1 as described in the table below:

	Level 1
Marketable securities:
August 31, 2013	$	956,376
August 31, 2012	$	200,311

As of August 31, 2013 the Group owns approximately 11.1% of D.N.A's outstanding ordinary shares. For information regarding sales of D.N.A shares by the Group after balance sheet date, see note 17a.

Transfers in and/or out of level 3 are recognized in the beginning of the reporting period.

The following table summarizes the activity for those financial assets where fair value measurements are estimated utilizing Level 3 inputs:

	August 31
	2013			2012
Carrying value at the beginning of the period	$	-		$	384,565
Additions		628,630			-
Reclassification to level 1		(628,630	)		(384,565	)
Carrying value at the end of the period	$	-		$	-

As of August 31, 2013, the carrying amount of cash and cash equivalents, short term deposits, accounts receivable, other current assets and accounts payables and accrued expenses approximates their fair values due to the short-term maturities of these instruments.

The fair value of long-term deposits also approximates their carrying value, since they bear interest at rates close to the prevailing market rates. The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

PREPAID EXPENSES AND OTHER CURRENT ASSETS

12 Months Ended

Aug. 31, 2013

PREPAID EXPENSES AND OTHER CURRENT ASSETS [Abstract]

PREPAID EXPENSES AND OTHER CURRENT ASSETS

NOTE 4 - PREPAID EXPENSES AND OTHER CURRENT ASSETS:

Composition of prepaid expenses and other current assets, grouped by major classifications, is as follows:

	August 31
	2013		2012

Tax Authorities	$	59,898	$	53,341
Prepaid expenses and other receivables		30,205		36,657
	$	90,103	$	89,998

PROPERTY AND EQUIPMENT, NET

12 Months Ended

Aug. 31, 2013

PROPERTY AND EQUIPMENT, Net [Abstract]

PROPERTY AND EQUIPMENT, Net

NOTE 5 - PROPERTY AND EQUIPMENT, NET:

Composition of property and equipment, grouped by major classifications, is as follows:

	August 31
	2013		2012
Cost:
Leasehold improvements	$	76,029	$	76,029
Office furniture and equipment		19,941		19,941
Computers and peripheral equipment		34,301		29,642
		130,271		125,612
Less - accumulated depreciation and amortization		124,503		120,844
	$	5,768	$	4,768

Depreciation expenses totaled $5,379 and $14,737 in the years ended August 31, 2013 and 2012, respectively.

WARRANTS

12 Months Ended

Aug. 31, 2013

WARRANTS [Abstract]

WARRANTS

NOTE 6 - WARRANTS

As part of the Company's private placements, warrants were granted to the Leading Investor, as defined in note 9c. Warrants to purchase 182,292 shares were granted in January 2011 (the "2011 Warrants"), warrants to purchase 112,613 shares were granted in August 2012 (the "August 2012 Warrants") and warrants to purchase 16,892 shares were granted in November 2012 (together, with the 2011 Warrants and the August 2012 Warrants, the "Three Warrants"). Each warrant was granted for five years at an initial exercise price of $6.00 per share. The warrants included a full ratchet anti-dilution protection from the second year anniversary date after issuing the warrant, subject to certain limitations and while the warrant was outstanding. In the event the Company was to issue or sell any common stock for a consideration per share lower than the exercise price then in effect, or was to issue or sell any options, warrants or other rights for the purchase or acquisition of such shares at a consideration per share of less than the exercise price then in effect, the warrants were to be amended to (a) reduce the exercise price to an amount equal to the per share consideration payable to the company in such sale or issuance, and (b) the quantity of warrants were to be updated, based on certain rules as determined in the Warrants Agreements with the Leading Investor.

As a result of a private placement in August 2012, and pursuant to adjustment of the terms of the 2011 Warrants, such warrants were amended to: (i) reduce the exercise price from $6.00 to $4.44, (ii) increase the number of shares issuable upon the exercise of the warrant from 182,292 to 246,341.

In addition, as a result of the agreement with D.N.A from October 2012, as described in note 9e, and pursuant to adjustment terms of the 2011 Warrants, the Company further amended the 2011 Warrants by: (i) reducing the exercise price from $4.44 to $3.7656 and (ii) increasing the number of shares issuable upon the exercise of the 2011 Warrants from 246,341 to 290,459.

On November 29, 2012, the Company and the Leading Investor entered into a letter agreement (the "Agreement") in connection with the Three Warrants. Pursuant to the Agreement, the Company and the Leading Investor agreed to amend the Three Warrants to provide that the anti-dilution protection of each of the Three Warrants shall be removed in its entirety. In addition, as to the Warrants issued in August and November 2012, the parties agreed that the exercise price shall be reduced to $3.7656. On that day, the Company also issued to the Leading Investor a Common Stock Purchase Warrant (the "New Warrant") pursuant to which, the Leading Investor shall have the right to purchase up to 137,311 shares of the Company over a period of four years at an exercise price of $7.20 per share. The fair value of the New Warrant at the date of grant was $145,173, using the following assumptions: dividend yield of 0% , expected term of 4 years, expected volatility of 62.29% and risk-free interest rate of 0.57%.

The fair value of the warrants was determined by using a Monte Carlo type model based on the risk neutral approach. The significant unobservable input used in the fair value measurement is the future expected issue dates. Significant delay in this input would result a higher fair value measurement.

In addition to the New Warrant, Nadav Kidron, the Company's President, Chief Executive Officer and director, in his personal capacity as a shareholder of the Company, undertook and agreed that following the execution and delivery of the Agreement, in the event that an adjustment pursuant to the anti-dilution protection of any of the Three Warrants (had it not been amended by the Agreement thereof) would have been triggered and the number of shares of common stock of the Company that the Leading Investor would have been able to purchase under the Three Warrants would have increased by an aggregate number in excess of 137,311 shares, then the Leading Investor shall have the right to purchase from Mr. Kidron such number of shares of common stock of the Company owned by Mr. Kidron equal to such excess, up to a maximum of 112,690 shares of common stock of the Company (the "Kidron Option"). The foregoing right shall survive until the expiration date of such Three Warrants. The fair value of the Kidron Option on the date of grant was $168,220, based on the Monte Carlo type model and was recognized as an expense against the stockholders equity.

Following the removal of the anti-dilution protection, the Three Warrants were no longer classified as liabilities. The Company recognized a financial expense in the amount of $296,982 during the three months ended November 30, 2012.

Financial liabilities carried at fair value as of August 31, 2013 and 2012, are classified in the table below in one of the three fair value categories:

	Fair value measurements at reporting date using
	Level 3		Total
Warrants -
August 31, 2013	$	-	$	-
August 31, 2012	$	637,182	$	637,182

The following table summarizes the activity for those financial liabilities where fair value measurements are estimated utilizing Level 3 inputs:

	Year ended August 31,			Year ended August 31,
	2013			2012
Carrying value at the beginning of the period	$	637,182		$	-
Additional warrant liabilities granted		28,344			494,478
Changes in fair value		(44,699	)		142,704
Exchange of warrants		(620,827	)		-
Carrying value at the end of the period	$	-		$	637,182

EMPLOYEES RIGHTS UPON RETIREMENT	12 Months Ended
EMPLOYEES RIGHTS UPON RETIREMENT	Aug. 31, 2013
EMPLOYEE RIGHTS UPON TERMINATION [Abstract]
EMPLOYEE RIGHTS UPON TERMINATION	NOTE 7 - EMPLOYEES RIGHTS UPON RETIREMENT: The Subsidiary is required to make a severance payment upon dismissal of an employee, or upon termination of employment in certain circumstances. The severance pay liability to the employees (based upon length of service and the latest monthly salary - one month's salary for each year employed) is recorded on the Subsidiary's balance sheets under "Liability for employee rights upon retirement." The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis. The liability is funded in part by the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the Subsidiary's balance sheets under "Funds in respect of employee rights upon retirement." These policies are the Subsidiary's assets. However, under labor agreements and subject to certain limitations, any policy may be transferred to the ownership of the individual employee for whose benefit the funds were deposited. In the years ended August 31, 2013 and 2012, the Subsidiary deposited $2,090 and $3,620, respectively, with insurance companies in connection with its severance payment obligations. In accordance with the current employment agreements with certain employees, the Subsidiary makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee's rights upon retirement. The Subsidiary is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Subsidiary's balance sheets, as the amounts funded are not under the control and management of the Subsidiary and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the "Contribution Plans"). The amounts of severance pay expenses were $23,331 and $5,615 for the years ended August 31, 2013 and 2012, respectively. $12,592 and $7,089 in the years ended August 31, 2013 and 2012, respectively, were in respect of a Contribution Plan. The Subsidiary expects to contribute approximately $25,480 in the year ending August 31, 2014 to insurance companies in connection with its severance liabilities for its operations for that year, $22,835 of which will be contributed to one or more Contribution Plans.

COMMITMENTS

12 Months Ended

Aug. 31, 2013

COMMITMENTS [Abstract]

COMMITMENTS

NOTE 8 - COMMITMENTS:

On September 11, 2011, the Subsidiary entered into an agreement with Hadasit, Dr. Miriam Kidron and Dr. Daniel Schurr (the "Agreement"), to retain consulting and clinical trial services. According to the Agreement, Hadasit will be entitled to a consideration of $200,000 to be paid by the Company in accordance with the actual progress of the study, $50,000 of which were paid and recognized through August 31, 2013. See also note 1a(1).

The Subsidiary has entered into operating lease agreements for vehicles used by its employees for a period of 3 years.

The lease expenses for the years ended August 31, 2013 and 2012 were $29,603 and $29,543, respectively.

The future lease payments under the lease agreement are $24,603, $17,615 and $7,340 for the years ending August 31, 2014, 2015 and 2016, respectively.

As security for its obligation under the lease agreements the Subsidiary deposited $1,959, which are classified as long term deposits.

On July 5, 2010, the Subsidiary of the Company entered into a Manufacturing Supply Agreement ("MSA") with Sanofi-Aventis Deutschland GMBH ("Sanofi"). According to the MSA, Sanofi will supply the subsidiary with specified quantities of recombinant human insulin to be used for clinical trials in the United States.

On February 15, 2011, the Subsidiary entered into a consulting agreement with a third party (the "Consultant") for a period of five years, pursuant to which the Consultant will provide consultation on scientific and clinical matters. The Consultant is entitled to a fixed monthly fee of $8,000, royalties of 8% of the net royalties actually received by the Subsidiary in respect of the patent that was sold to Entera on March 31, 2011 (see note 1a(1)) and an option to purchase up to 20,834 shares of the Company at an exercise price of $6.00 per share. The option vests in five annual installments commencing February 16, 2012 and expires on February 16, 2021. The initial fair value of the option on the date of grant was $62,185, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 78.65%; risk-free interest rates of 3.62%; and the remaining expected term of 10 years. The fair value of the option as of August 31, 2013 was $108,675, using the following assumptions: dividend yield of 0% and expected term of 7.46 years; expected volatility of 76.87%; and risk-free interest rate of 2.33%. The fair value of the option granted is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.

On July 25, 2011, the Company issued warrants to purchase 32,000 shares of the Company at an exercise price of $6.00 per share to a third party as remuneration for services to be rendered during the 12 month period commencing May 13, 2011. The warrants vest in twelve equal installments over the five years period form October 13, 2011 to May 13, 2016, and will expire on July 25, 2016. The fair value of these warrants on the date of grant was $5,057, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 77.39%; risk-free interest rate of 1.55%; and the remaining expected term of 5 years. The fair value of the option as of August 31, 2013, was $9,169, using the following assumptions: dividend yield of 0% and expected term of 2.9 years; expected volatility of 76.41%; and risk-free interest rate of 0.79%. The fair value of the option granted is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.

On February 15, 2012, the Company entered into an advisory agreement with a third party for a period of one year, pursuant to which such third party will provide investors relations services and will be entitled to a share based compensation as follows: 25,000 shares of the Company will be issued in six installments over the engagement period, commencing February 15, 2012, and a warrant to purchase 62,500 shares of the Company at an exercise price of $6.00 per share. The warrant vested in 12 monthly installments commencing February 15, 2012 and expires on February 15, 2017. The initial fair value of the warrant on the date of grant was $121,304, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.82%; risk-free interest rates of 0.81%; and the remaining expected term of 5 years.

On July 3, 2012, the Company and the third party entered into an amendment to the agreement, according to which the original agreement was extended until July 3, 2013, and a new vesting schedule was determined for the remainder of the share based compensation until July 3, 2013. The change in the vesting schedule did not have any material effect on the expenses related to this advisory agreement. The Company records expenses in respect of this warrant during the term of the services.

The fair value of the warrant as of June 15, 2013, the date of the last vesting installment, was $164,752, using the following assumptions: dividend yield of 0% and expected term of 4.0 years; expected volatility of 76.16%; and risk-free interest rate of 0.77%. The fair value of the warrant granted is recognized over the related service period using the straight-line method.

On March 18, 2012, the Subsidiary entered into a lease agreement for its facilities in Israel. The lease agreement is for a period of 57 months commencing January 1, 2012.

The annual lease expenses for the years ended August 31, 2013 and 2012 were approximately $13,116 and $9,132, respectively.

On April 28, 2013, the Subsidiary entered into a new lease agreement for its office facilities in Israel. The new lease agreement is for a period of 36 months commencing October 1, 2013. The annual lease payment will be NIS 89,052 from 2014-2016, and will be linked to the increase in the Israeli consumer price index (as of August 31, 2013, the future annual lease payments under the new agreement will be $24,641, based on the exchange rate as of August 31,2013).

As security for its obligation under this lease agreement the Company provided a bank guarantee in an amount equal to three monthly lease payments.

On April 15, 2013, the Company entered into a consulting agreement with a third party advisor for a period of twelve months, pursuant to which such advisor provided investor relations services and received a monthly cash fee and 15,000 shares of the Company to be issued in three equal installments, on each of May 1, 2013, August 1, 2013 and November 15, 2013. On July 11, 2013 the Company issued to such advisor 5,000 shares. The fair value of the shares at this date was $34,900. The Company issued the remaining 10,000 shares on November 4, 2013, see also note 9f.

On April 29, 2013, the Subsidiary entered into a Clinical Research Organization Service Agreement with a third party, to retain it as a CRO, for its Phase 2a clinical trial for an oral insulin capsule. As consideration for its services, the subsidiary will pay the CRO a total amount of approximately $332,702 that will be paid during the term of the engagement and based on achievement of certain milestones, $89,830 of which were paid and recognized through August 31, 2013.

On July 23, 2013, the Subsidiary entered into a Master Service Agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of $102,280, of which $30,684 were paid and recognized through August 31, 2013.

Grants from Bio-Jerusalem

The Subsidiary is committed to pay royalties to the Bio-Jerusalem fund on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received by the Company (Israeli CPI linked) at the total amount of $65,053. As of August 31, 2013, the Subsidiary had not yet realized any revenues and did not incur any royalty liability.

During the year ended August 31, 2013, the Company received $12,319 from the Bio-Jerusalem fund. For the period from inception on April 12, 2002 through August 31, 2013, the research and development expenses are presented net of Bio-Jerusalem grants, in the total amount of $65,053.

Grants from the Chief Scientist Office ("OCS")

Under the terms of the Company's funding from the Israeli Government, royalties of 3%-3.5% are payable on sales of products developed from a project so funded, up to 100% of the amount of the grant received by the Company (dollar linked) with the addition of annual interest at a rate based on LIBOR.

At the time the grants were received, successful development of the related projects was not assured. In case of failure of a project that was partly financed as above, the Company is not obligated to pay any such royalties.

On August 31, 2013, the Subsidiary had not yet realized any revenues from the said project and did not incur any royalty liability. The total amount that was actually received through August 31, 2013 was $1,659,338.

For the years ended August 31, 2013, and 2012, and for the period from inception on April 12, 2002 through August 31, 2013, the research and development expenses are presented net of OCS Grants, in the total amount of $296,836, $372,959 and $1,717,392, respectively.

STOCKHOLDERS' EQUITY

12 Months Ended

Aug. 31, 2013

STOCK HOLDERS' EQUITY [Abstract]

STOCK HOLDERS' EQUITY

NOTE 9 - STOCKHOLDERS' EQUITY:

In February 2013 the Company's common stock began trading on the Nasdaq Capital Market under the symbol ORMP. Before then it was traded on the Over-The-Counter Bulletin Board.

The following are capital stock transactions that took place during the years ended August 31, 2013 and 2012:

On August 15, 2011, the Company entered into a consulting agreement with a third party advisor for a period of nine months, pursuant to which such advisor provided investor relations services and received a monthly cash fee and shares of the Company's that were issued in three equal installments as follows: on each of December 12, 2011, March 14, 2012 and May 15, 2012, the Company issued 6,917 shares at a fair value of $24,900, $26,560 and $24,900, respectively.

Under the terms of the advisory agreement, as described in note 8f, on each of March 14, 2012 and July 5, 2012, the Company issued 4,167 shares to such advisor as remuneration for services provided. The fair value of the shares at the dates of grant was $15,500 and $16,000, respectively. The Company issued the remaining 16,667 shares on July 30, 2013 at a fair value of $123,336.

In August 2012, the Company entered into Securities Purchase Agreements with a number of investors for the sale of 801,942 units at a purchase price of $4.44 per unit for total consideration of $3,560,192. Each unit consisted of one share of the Company and one common stock purchase warrant. Each warrant entitles the holder to purchase half a share exercisable for five years at an exercise price of $6.00 per share. The investors were granted customary registration rights with respect to resales of shares, including the shares underlying the warrants. In addition, one of the investors who was previously defined as a leading investor (the "Leading Investor"), who purchased 225,226 of the units, was granted the right to maintain its percentage of the shares of the Company's common stock outstanding by purchasing more shares whenever the Company proposes to issue certain additional shares to other investors. Such right only exists so long as such investor holds at least 5% of the Company's outstanding common stock. In addition, such investor's warrants contained anti-dilution protection (the "full ratchet anti-dilution protection") and cashless exercise provisions not contained in the other investors' warrants. The other terms of the Leading Investor's Securities Purchase Agreement were substantially the same as those granted to him in 2011 for his first investment. As to the amendment to the 2011 Warrants, see note 6.

In addition, in August 2012, the Company entered into a Securities Purchase Agreement with an investor for the sale of 5,652 units at same terms as describe above. As the payment from said investor was received during September 2012, following which, the Company issued him 5,652 shares of its common stock and a warrant to purchase 2,826 shares of its common stock, the proceeds from that investment, of $25,093 were presented as shares and warrants to be issued for cash.

The Company paid cash consideration of $71,250 as finders' fees in connection with the Securities Purchase Agreements.

Between September and November 2012, the Company entered into Securities Purchase Agreements with a number of investors for the sale of 329,872 units at a purchase price of $4.44 per unit for total consideration of $1,464,425. Each unit consisted of one share of the Company's common stock and one common stock purchase warrant. Each warrant entitles the holder to purchase 0.50 a share of common stock exercisable for five years at an exercise price of $6.00 per share. The investors were granted customary registration rights with respect to resales of shares, including the shares underlying the warrants. The Leading Investor purchased 33,784 of the units and was granted the same rights as described in note 9c above. See also note 6 regarding the removal of the full ratchet anti-dilution protection.

As a finder's fee, in connection with the securities purchase agreements, the Company paid cash consideration of $12,885, as well as issued 1,127 shares of the Company and 564 common stock purchase warrant to another individual. The Company also issued 12,745 shares of the Company and 6,373 common stock purchase warrants to a director as a finder's fee with respect to the Securities Purchase Agreements described above and to the Securities Purchase Agreements to which the Company had entered into in August 2012.

On October 30, 2012, the Company entered into a Securities Purchase Agreement with D.N.A, according to which, the Company issued on that day to D.N.A 199,172 shares of its common stock, in consideration for the option to purchase up to 21,637,611 ordinary shares of D.N.A, valued at approximately $628,630 at the day of the transaction. The Company exercised the option in February 2013. See also note 3.

As described in note 8h, on July 11, 2013, the Company issued 5,000 shares of its common stock to an advisor as remuneration for services rendered.

On July 10, 2013, the Company entered into a Placement Agency Agreement with Aegis Capital Corp. as representative of the several placement agents (the "Placement Agents"), pursuant to which the Placement Agents agreed to use their reasonable best efforts to arrange for the sale of up to 658,144 shares of the Company's common stock. In connection therewith, on July 10, 2013, the Company also entered into a Securities Purchase Agreement, pursuant to which the Company agreed to sell an aggregate of 658,144 shares at a price of $7.00 per share, to various investors in a registered direct offering (the "Offering"). The Company had received all funds and issued all shares in connection with the Offering as of July 17, 2013. The net proceeds to the Company from the offering are approximately $4,238,889, after deducting Placement Agents' commissions of $255,246 and other offering expenses of the Company.

On July 8,2013, the Company issued 12,042 shares to four service providers as remuneration for investors relations services provided during the year ended August 31, 2013. The total fair value of the shares at the date of grant was $86,221.

As to shares issued as part of stock based compensation plan see note 10.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

STOCKBASED COMPENSATION

12 Months Ended

Aug. 31, 2013

STOCK BASED COMPENSATION [Abstract]

STOCK BASED COMPENSATION

NOTE 10 - STOCK BASED COMPENSATION:

As of August 31, 2013, the Company has one stock option plan (the "2008 Stock Option Plan"), under which, the Company had reserved a pool of 1,000,000 shares of the Company's common stock which may be issued at the discretion of the Company's Board of Directors from time to time. Under this Plan, each option is exercisable into one share of common stock of the Company.

The options may be exercised after vesting and in accordance with vesting schedules which will be determined by the Board of Directors for each grant. The maximum term of the options is 10 years.

The fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model. The volatility is based on a historical volatility, by statistical analysis of the weekly share price for past periods. The expected term is the length of time until the expected dates of exercising the options, based on estimated data regarding employees' exercise behavior.

The following are stock options transactions made during the years ended August 31, 2013 and 2012:

On August 8, 2012, options to purchase an aggregate of 144,000 shares of the Company were granted to Nadav Kidron, the Company's President, Chief Executive Officer and director, and Miriam Kidron, the Company's Chief Medical and Technology Officer and director, both related parties, at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant), the options vested with respect to 42,000 shares of common stock immediately on the date of grant and the remaining shares of common stock will vest in seventeen equal monthly installments of 6,000 each. These options expire on August 7, 2022. The fair value of these options on the date of grant was $373,565, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 0.83%; and expected term of 5.5 years.

On August 8, 2012, options to purchase an aggregate of 43,334 shares of the Company were granted to three Board of Directors members at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant). The options vest in two equal annual installments, commencing January 1, 2013, and expire on August 7, 2022. The fair value of these options on the date of grant was $114,694, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 1.0375%; and expected term of 5.75 years.

On August 8, 2012, options to purchase 50,750 shares of the Company were granted to an employee of the Subsidiary, at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant). The options vest in 29 equal monthly installments, commencing August 31, 2012, and expire on August 8, 2022. The fair value of these options on the date of grant was $134,324, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 1.0375%; and expected term of 5.75 years.

On August 8, 2012, options to purchase 6,250 shares of the Company c granted to an employee of the Subsidiary, at an exercise price of $4.08 per share (equivalent to the traded market price on the date of grant). The options vest in three equal annual installments, commencing January 1, 2013, and expire on August 7, 2022. The fair value of these options on the date of grant was $16,780, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 76.03%; risk-free interest rates of 0.935%; and expected term of 6 years.

August 8, 2012, the Company's Board of Directors approved an extension of the term of the warrants to purchase 280,114 shares of the Company held by Dr. Miriam Kidron by approximately two years from such approval, expiring on August 6, 2014. The incremental fair value of the warrant extension was negligible.

On December 20, 2012, options to purchase 20,000 shares of the Company were granted to a director at an exercise price of $6.00 per share (higher than the traded market price on the date of grant). The options vest in two equal annual installments, commencing January 1, 2013, and expire on December 19, 2022. The fair value of these options on the date of grant was $41,402, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 64.35%; risk-free interest rates of 1.01%; and expected term of 5.75 years.

On December 20, 2012, options to purchase 4,667 shares of the Companywere granted to an employee of the Subsidiary at an exercise price of $6.00 per share (higher than the traded market price on the date of grant). The options vest in two equal annual installments, commencing June 1, 2013, and expire on December 19, 2022. The fair value of these options on the date of grant was $9,660, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 64.35%; risk-free interest rates of 1.01%; and expected term of 5.75 years.

On April 14, 2013, options to purchase 100,800 shares of the Company's common stock were granted to an employee of the Subsidiary at an exercise price of $7.88 per share (equal to the traded market price on the date of grant). The options vest in 35 consecutive equal installments during a 3-year period commencing on May 31, 2013, and two installments of 1,400 shares of common stock each, that will vest on April 30, 2013 and April 14, 2016, and expire on April 14, 2023. The fair value of these options on the date of grant was $519,785, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 75.46%; risk-free interest rates of 0.92%; and expected term of 6 years .

As to options granted to third parties, see notes 8d, 8e and 8f.

The fair value of each option grant is estimated on the date of grant using the Black Scholes option-pricing model with the following assumptions:

	For options granted in
	the year ended August 31
	2013		2012
Expected option life (years)		5.75-6		5.5-5.75
Expected stock price volatility (%)		64.35-75.46		76.03
Risk free interest rate (%)		0.92-1.01		0.83-1.0375
Expected dividend yield (%)		0.0		0.0

A summary of the status of the stock options granted to employees and directors as of August 31, 2013 and 2012, and changes during the years ended on those dates, is presented below:

	Year ended August 31,
	2013				2012
			Weighted					Weighted
	Number		average		Number			average
	of		exercise		of			exercise
	options		price		options			price
			$					$
Options outstanding at
beginning of year		932,116		3.72		834,117			3.84
Changes during the year:
Granted - at market price		100,800		7.88		244,334			4.08
Granted - above market price		24,667		6.00		-
Expired		-				(141,667	)		5.40
Forfeited		-				(4,667	)		5.64
Exercised		8,334		5.04		-
Options outstanding at end
of year		1,049,249		4.13		932,116			3.72
Options exercisable at end
of year		870,883				717,088
Weighted average fair
value of options granted
during the year	$	4.55			$	2.65

Costs incurred in respect of stock based compensation for employees and directors, for the years ended August 31, 2013 and 2012 were $562,966 and $200,866, respectively.

The total intrinsic value of employees options exercised during the year ended August 31, 2013, was $17,584. No options were exercised during the year ended August 31, 2012.

The following table presents summary information concerning the options granted to employees and directors outstanding as of August 31, 2013:

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	outstanding		Life		price		intrinsic value
$			Years		$		$
0.012		280,114		0.93		0.012		2,038,670
4.08 to 6.48		668,335		7.05		5.28		1,340,874
7.88		100,800		9.62		7.88		-
		1,049,249		5.66		4.13		3,379,544

The following table presents summary information concerning the options granted to employees and directors exercisable as of August 31, 2013:

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	exercisable		Life		price		intrinsic value
$			Years		$		$
0.012		280,114		0.93		0.012		2,038,670
4.08 to 6.48		578,169		6.74		5.43		1,075,120
7.88		12,600		9.62		7.88		-
		870,883		4.92		3.72		3,113,790

As of August 31, 2013, there were $475,485 of unrecognized compensation costs related to non-vested employees and directors, to be recorded over the next 32 months.

A summary of the status of the stock options granted to non-employees outstanding as of August 31, 2013, and changes during the years ended on this date, is presented below:

	Year ended August 31
	2013				2012
			Weighted				Weighted
	Number		average		Number		average
	of		exercise		of		exercise
	options		price		options		price
			$				$
Options outstanding at
beginning of year		144,856		6.66		82,356		7.20
Changes during the year:
Granted above market
price		-				62,500		6.00
Options outstanding at end
of year		144,856		6.66		144,856		6.66
Options exercisable at end
of year		109,969				88,689

The Company recorded stock compensation of $156,253 and $117,098 during the years ended August 31, 2013 and 2012, respectively, related to consulting services.

The following table presents summary information concerning the options granted to non-employees outstanding as of August 31, 2013:

			Weighted
			Average		Weighted
Range of			Remaining		Average
exercise	Number		Contractual		Exercise		Aggregate
prices	outstanding		Life		Price		intrinsic value
$			Years		$		$
4.08 to 6.00		111,520		3.79		5.93		151,785
9.12		33,336		4.33		9.12		-
		144,856		3.92		6.66		151,785

The following table presents summary information concerning the options granted to non-employee exercisable as of August 31, 2013:

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	exercisable		Life		price		intrinsic value
$			Years		$		$
4.08 to 6.00		93,301		3.42		5.92		128,283
9.12		16,668		4.33		9.12		-
		109,969		3.55		6.40		128,283

As of August 31, 2013 there were $52,949 of unrecognized compensation costs related to non-vested non-employee options, to be recorded over the next 33 months.

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

12 Months Ended

Aug. 31, 2013

ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 11 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES:

	Year ended
	August 31,
	2013		2012

Service providers	$	392,289	$	580,714
Payroll and related expenses		58,652		16,459
	$	450,941	$	597,173

RESEARCH AND DEVELOPMENT EXPENSES, NET

12 Months Ended

Aug. 31, 2013

RESEARCH AND DEVELOPMENT EXPENSES, NET [Abstract]

RESEARCH AND DEVELOPMENT EXPENSES, NET

NOTE 12 - RESEARCH AND DEVELOPMENT EXPENSES, NET:

							Period from April
							12, 2002
							(inception)
	Year ended						through
	August 31,						August 31,
	2013			2012			2013

Clinical trials	$	1,341,471		$	1,298,310		$	6,504,824
Payroll and consulting fees		447,195			385,646			2,368,728
Costs for registration of patents		106,687			110,811			558,297
Compensation costs in respect of options granted to employees, directors and consultants		346,961			98,688			3,268,842
Other		338,635			160,350			886,242
Less - grants from the OCS and Bio Jerusalem Fund		(309,155	)		(372,959	)		(1,782,445	)
	$	2,271,794		$	1,680,845		$	11,804,488

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

GENERAL AND ADMINISTRATIVE EXPENSES

12 Months Ended

Aug. 31, 2013

GENERAL AND ADMINISTRATIVE EXPENSES [Abstract]

GENERAL AND ADMINISTRATIVE EXPENSES

NOTE 13 - GENERAL AND ADMINISTRATIVE EXPENSES

					Period from April
					12, 2002
					(inception)
	Year ended				through
	August 31				August 31,
	2013		2012		2013

Compensation costs in respect of options granted to employees, directors and consultants	$	372,258	$	172,470	$	2,421,664
Professional services		439,175		221,218		2,338,919
Consulting fees		259,670		159,136		1,230,570
Travel costs		127,196		71,529		673,126
Write off of debt		-		-		275,000
Business development		308,183		284,899		1,124,128
Payroll and related expenses		230,191		144,101		983,399
Insurance		43,399		22,375		162,320
Other		252,057		127,436		984,550
	$	2,032,129	$	1,203,164	$	10,193,676

FINANCIAL INCOME AND EXPENSES

12 Months Ended

Aug. 31, 2013

FINANCIAL INCOME AND EXPENSES [Abstract]

FINANCIAL INCOME AND EXPENSES

NOTE 14 - FINANCIAL INCOME AND EXPENSES

Financial income

	Year ended August 31
	2013		2012
Gain on sale of marketable securities (note 3)	$	90,370	$	-
Changes in fair value of warrants		44,699		-
Income from interest		18,728		13,126
Other		26,698		-
	$	180,495	$	13,126

Financial expenses

	Year ended August 31
	2013		2012
Exchange of warrants	$	296,982	$	-
Changes in fair value of warrants		-		142,704
Exchange rate differences		2,804		35,067
Bank commissions		13,660		14,952
Other		-		6,400
	$	313,446	$	199,123

TAXES ON INCOME

12 Months Ended

Aug. 31, 2013

TAXES ON INCOME [Abstract]

TAXES ON INCOME

NOTE 15 - TAXES ON INCOME:

Taxes on income included in the consolidated statements of operations represent current taxes due to taxable income of the Company and its Subsidiary.

Corporate taxation in the U.S.

The applicable corporate tax rate for the Company is 35%.

As of August 31, 2013, the Company has an accumulated tax loss carryforward of approximately $5,605,237 (as of August 31, 2012, approximately $4,896,605). Under U.S. tax laws, carryforward tax losses expire 20 years after the year in which incurred. In the case of the Company, the net loss carryforward will expire in the years 2025 through 2032.

Corporate taxation in Israel:

The Subsidiary is taxed in accordance with Israeli tax laws. The corporate tax rate applicable to 2012 and 2013 is 25%.

On August 5, 2013, the Law for Change of National Priorities (Legislative Amendments for Achieving the Budgetary Goals for 2013-2014), 2013 was published in Reshumot (the Israeli government official gazette), enacting, among other things, the following raising the corporate tax rate beginning in 2014 and thereafter to 26.5% (instead of 25%).

As of August 31, 2013, the Subsidiary has an accumulated tax loss carryforward of approximately $7,663,790 (as of August 31, 2012, approximately $5,905,361).

Deferred income taxes:

	August 31
	2013			2012
In respect of:
Net operating loss carryforward		3,992,737			3,190,152
Research and development expenses		338,908			18,008
Less - Valuation allowance		(4,331,645	)		(3,208,160	)
Net deferred tax assets		-,-			-,-

Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a full valuation allowance.

Loss before taxes on income and income taxes included in the income statements of operations:

							Period from April
							12, 2002
							(inception)
	Year ended						through
	August 31						August 31,
	2013			2012			2013
Loss before taxes on income:
U.S.		1,185,831			599,067			9,626,374
Outside U.S.		3,251,044			2,655,193			12,461,502
	$	4,436,874		$	3,254,260		$	22,087,875
Income tax expenses (benefit):
Current:
U.S.		(12,960	)		(7,569	)		67,392
Outside U.S.		(192,102	)		97,787			108,440
	$	(205,062	)	$	90,218		$	175,832

Reconciliation of the statutory tax benefit to effective tax expense

Following is a reconciliation of the theoretical tax expense, assuming all income is taxed at the regular tax rates applicable to companies in the United States, and the actual tax expense:

							Period from April
							12, 2002
							(inception)
	Year ended						through
	August 31						August 31,
	2013			2012			2013
Loss before income taxes as reported in
the consolidated statement of operations	$	(4,436,874	)	$	(3,254,260	)	$	(22,087,875	)
Statutory tax benefit		(1,522,906	)		(1,138,991	)		(7,700,757	)
Increase (decrease) in income taxes
resulting from:
Change in the balance of the valuation
allowance for deferred tax		902,509			516,749			3,573,334
Disallowable deductions		374,059			120,156			2,617,605
Increase in taxes resulting from
different tax rates applicable to the
Subsidiary		276,338			502,086			1,588,322
Uncertain tax position		(205,062	)		90,218			23,210
Taxes on income for the reported year	$	(205,062	)	$	90,218		$	35,714

Uncertainty in Income Taxes

ASC No.740 "Income Taxes" requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. The Company recognizes interest and penalties related to its tax contingencies as income tax expense. As of August 31, 2013 and 2012, the Company recorded zero and $15,539, respectively, of penalties related to tax contingencies.

The following table summarizes the activity of the Company unrecognized tax benefits:

	Year ended August 31
	2013			2012
Balance at Beginning of Year	$	228,272		$	138,054
Increase (decrease) in uncertain tax positions for the current year		(205,062	)		90,218
Balance at End of Year	$	23,210		$	228,272

The decrease in uncertain tax positions for the year ended August 31, 2013, is a result of the expiration of the statute of limitations with respect to the 2008 tax year of the Subsidiary.

The Company does not expect unrecognized tax expenses to change significantly over the next 12 months.

The Company is subject to U.S. Federal income tax examinations for the tax years of 2008 through 2013.

The Subsidiary is subject to Israeli income tax examinations for the tax years of 2009 through 2013.

RELATED PARTIES - TRANSACTIONS

12 Months Ended

Aug. 31, 2013

RELATED PARTIES - TRANSACTIONS

NOTE 16 - RELATED PARTIES - TRANSACTIONS:

During each of the fiscal years of 2013 and 2012 the Company paid to directors $39,361 and $30,000, respectively, for managerial services.

As to the agreements with Hadasit, see note 8a.

On July 1, 2008, the Subsidiary entered into a consulting agreement with KNRY Ltd. ("KNRY"), an Israeli company owned by Nadav Kidron, whereby Mr. Nadav Kidron, through KNRY, will provide services as President and Chief Executive Officer of both Oramed and the Subsidiary (the "Nadav Kidron Consulting Agreement"). Additionally, on July 1, 2008, the Subsidiary entered into a consulting agreement with KNRY whereby Dr. Miriam Kidron, through KNRY, will provide services as Chief Medical and Technology Officer of both Oramed and the Subsidiary (the "Miriam Kidron Consulting Agreement" and together with the Nadav Kidron Consulting Agreement, the "Consulting Agreements"). The Consulting Agreements replaced the employment agreements entered into between the Company and KNRY, dated as of August 1, 2007, pursuant to which Nadav Kidron and Miriam Kidron, respectively, provided services to the Company and the Subsidiary. The Consulting Agreements are both terminable by either party upon 60 days prior written notice. The Consulting Agreements provide that KNRY (i) will be paid, under each of the Consulting Agreements, in NIS a gross amount of NIS 50,400 per month (as of August 31, 2012 the monthly payment in the Company's functional currency was $12,512) and (ii) will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements.

On July 17, 2013, the Subsidiary entered into amendments to the Consulting Agreements with KNRY, according to which, Nadav Kidron's annual payment was set at $250,000, and in addition to such payment he will be granted the use of a company car and a one time cash bonus of $60,000, and Miriam Kidron's annual payment was set at $200,000, and in addition to such payment she was granted the use of a company car and a one time cash bonus of $20,000, both effective July 1, 2013.

As to options granted to related parties, see notes 10a and 10f.

Balances with related parties:

	August 31
	2013		2012
Accounts Receivable - KNRY	$	1,377	$	404
Accounts Receivable - Nadav Kidron*	$	3,153		-
Accounts payable and accrued expenses - KNRY	$	64,355		-

* Down payment for travel expenses.

Expenses to related parties:

	August 31
	2013		2012
KNRY	$	448,080	$	318,271

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

SUBSEQUENT EVENTS

12 Months Ended

Aug. 31, 2013

SUBSEQUENT EVENTS [Abstract]

SUBSEQUENT EVENTS

NOTE 17 - SUBSEQUENT EVENTS:

During October and November 2013, the Subsidiary sold in aggregate of 1,025,991 of the D.N.A shares for a total of $43,208. As of November 25, 2013, the Group owns approximately 10.6% of D.N.A's outstanding ordinary shares.

In November 2013, the Company issued 10,000 shares to an advisor. See also note 8h.

SIGNIFICANT ACCOUNTING POLICIES (Policy)

12 Months Ended

Aug. 31, 2013

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

General

Incorporation and operations

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

Development and liquidity risks

The Company has been in the development stage since its formation and has not yet generated any revenues from its operations.

Reverse stock split

Accounting principles

b.	Accounting principles

The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP").

Use of estimates in the preparation of financial statements

c.	Use of estimates in the preparation of financial statements

Functional currency

d.	Functional currency

Principles of consolidation

e.	Principles of consolidation

The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation.

Property and equipment

f.	Property and equipment

Property and equipment are recorded at cost and depreciated by the straight-line method over the estimated useful lives of the assets.

Annual rates of depreciation are as follows:

	%
Computers and peripheral equipment		33
Office furniture and equipment		15-33

Leasehold improvements are amortized over the term of the lease which is shorter than the estimated useful life of the improvements.

Income taxes

g.	Income taxes

1. Deferred taxes

2. Uncertainty in income tax

Research and development

h.	Research and development, net

Cash equivalents

i.	Cash equivalents

Loss per common share

Impairment in value of long-lived assets

k.	Impairment in value of long-lived assets

Stock based compensation

l.	Stock based compensation

Warrants issued as part of capital raisings that are classified as a liability

m.	Warrants issued as part of capital raisings that are classified as a liability

Warrants that entitle the holder to down-round protection (through ratchet and anti-dilution provisions) are classified as liabilities in the statement of financial position.

The liability is measured both initially and in subsequent periods at fair value, with changes in fair value charged to finance expenses, net. See note 6.

Fair value measurement

n.	Fair value measurement:

Level 1:

Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2:

Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3:

Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of August 31, 2013 the assets or liabilities measured at fair value comprise of available for sale securities (level 1).

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent.

In order to secure the fulfillment of the Company's obligations under the derivatives agreements, the Company has placed a restricted deposit with the bank in an amount of $16,000.

Concentration of credit risks

o.	Concentration of credit risks

Newly issued and recently adopted accounting pronouncements

p.	Newly issued and recently adopted accounting pronouncements:

SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Aug. 31, 2013

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Schedule of Annual Depreciation Rates

	%
Computers and peripheral equipment		33
Office furniture and equipment		15-33

SHORT TERM INVESTMENTS (Tables)

12 Months Ended

Aug. 31, 2013

SHORT TERM INVESTMENTS [Abstract]

Schedule of Short Term Investments

August 31
	2013				2012
	Annual interest rate		Amount		Annual interest rate		Amount
Dollar deposits		0.6-1.06%	$	5,111,914		0.85%	$	260,371
NIS deposits		1.93%		134,713		1.93-1.97%		194,010
			$	5,246,627			$	454,381

MARKETABLE SECURITIES (Tables)

12 Months Ended

Aug. 31, 2013

MARKETABLE SECURITIES [Abstract]

Schedule of Marketable Securities Carried at Fair Value

	Level 1
Marketable securities:
August 31, 2013	$	956,376
August 31, 2012	$	200,311

Schedule of Financial Assets Measured Using Unobservable Inputs

	August 31
	2013			2012
Carrying value at the beginning of the period	$	-		$	384,565
Additions		628,630			-
Reclassification to level 1		(628,630	)		(384,565	)
Carrying value at the end of the period	$	-		$	-

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)

12 Months Ended

Aug. 31, 2013

PREPAID EXPENSES AND OTHER CURRENT ASSETS [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

	August 31
	2013		2012

Tax Authorities	$	59,898	$	53,341
Prepaid expenses and other receivables		30,205		36,657
	$	90,103	$	89,998

PROPERTY AND EQUIPMENT, NET (Tables)

12 Months Ended

Aug. 31, 2013

PROPERTY AND EQUIPMENT, Net [Abstract]

Schedule of Property and Equipment

	August 31
	2013		2012
Cost:
Leasehold improvements	$	76,029	$	76,029
Office furniture and equipment		19,941		19,941
Computers and peripheral equipment		34,301		29,642
		130,271		125,612
Less - accumulated depreciation and amortization		124,503		120,844
	$	5,768	$	4,768

WARRANTS (Tables)

12 Months Ended

Aug. 31, 2013

WARRANTS [Abstract]

Schedule of Warrants Carried at Fair Value

	Fair value measurements at reporting date using
	Level 3		Total
Warrants -
August 31, 2013	$	-	$	-
August 31, 2012	$	637,182	$	637,182

Schedule of Liabilities Measured at Fair Value Using Significant Unobservable Inputs

	Year ended August 31,			Year ended August 31,
	2013			2012
Carrying value at the beginning of the period	$	637,182		$	-
Additional warrant liabilities granted		28,344			494,478
Changes in fair value		(44,699	)		142,704
Exchange of warrants		(620,827	)		-
Carrying value at the end of the period	$	-		$	637,182

STOCKBASED COMPENSATION (Tables)

12 Months Ended

Aug. 31, 2013

STOCK BASED COMPENSATION [Abstract]

Schedule of Fair Value Assumptions

	For options granted in
	the year ended August 31
	2013		2012
Expected option life (years)		5.75-6		5.5-5.75
Expected stock price volatility (%)		64.35-75.46		76.03
Risk free interest rate (%)		0.92-1.01		0.83-1.0375
Expected dividend yield (%)		0.0		0.0

Schedule of Stock Option Activity for Employees

	Year ended August 31,
	2013				2012
			Weighted					Weighted
	Number		average		Number			average
	of		exercise		of			exercise
	options		price		options			price
			$					$
Options outstanding at
beginning of year		932,116		3.72		834,117			3.84
Changes during the year:
Granted - at market price		100,800		7.88		244,334			4.08
Granted - above market price		24,667		6.00		-
Expired		-				(141,667	)		5.40
Forfeited		-				(4,667	)		5.64
Exercised		8,334		5.04		-
Options outstanding at end
of year		1,049,249		4.13		932,116			3.72
Options exercisable at end
of year		870,883				717,088
Weighted average fair
value of options granted
during the year	$	4.55			$	2.65

Summary of Information for Options Granted and Exercisable for Employees

The following table presents summary information concerning the options granted to employees and directors outstanding as of August 31, 2013:

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	outstanding		Life		price		intrinsic value
$			Years		$		$
0.012		280,114		0.93		0.012		2,038,670
4.08 to 6.48		668,335		7.05		5.28		1,340,874
7.88		100,800		9.62		7.88		-
		1,049,249		5.66		4.13		3,379,544

The following table presents summary information concerning the options granted to employees and directors exercisable as of August 31, 2013:

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	exercisable		Life		price		intrinsic value
$			Years		$		$
0.012		280,114		0.93		0.012		2,038,670
4.08 to 6.48		578,169		6.74		5.43		1,075,120
7.88		12,600		9.62		7.88		-
		870,883		4.92		3.72		3,113,790

Schedule of Stock Option Activity for Non-Employees

	Year ended August 31
	2013				2012
			Weighted				Weighted
	Number		average		Number		average
	of		exercise		of		exercise
	options		price		options		price
			$				$
Options outstanding at
beginning of year		144,856		6.66		82,356		7.20
Changes during the year:
Granted above market
price		-				62,500		6.00
Options outstanding at end
of year		144,856		6.66		144,856		6.66
Options exercisable at end
of year		109,969				88,689

Summary of Information for Options Granted and Exercisable for Non-Employees

The following table presents summary information concerning the options granted to non-employees outstanding as of August 31, 2013:

			Weighted
			Average		Weighted
Range of			Remaining		Average
exercise	Number		Contractual		Exercise		Aggregate
prices	outstanding		Life		Price		intrinsic value
$			Years		$		$
4.08 to 6.00		111,520		3.79		5.93		151,785
9.12		33,336		4.33		9.12		-
		144,856		3.92		6.66		151,785

The following table presents summary information concerning the options granted to non-employee exercisable as of August 31, 2013:

			Weighted
			Average		Weighted
Range of			Remaining		average
exercise	Number		Contractual		exercise		Aggregate
prices	exercisable		Life		price		intrinsic value
$			Years		$		$
4.08 to 6.00		93,301		3.42		5.92		128,283
9.12		16,668		4.33		9.12		-
		109,969		3.55		6.40		128,283

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)

12 Months Ended

Aug. 31, 2013

ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]

Schedule of Accounts Payable and Accrued Expenses

	Year ended
	August 31,
	2013		2012

Service providers	$	392,289	$	580,714
Payroll and related expenses		58,652		16,459
	$	450,941	$	597,173

RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)

12 Months Ended

Aug. 31, 2013

RESEARCH AND DEVELOPMENT EXPENSES, NET [Abstract]

Schedule of Research and Development Expenses

							Period from April
							12, 2002
							(inception)
	Year ended						through
	August 31,						August 31,
	2013			2012			2013

Clinical trials	$	1,341,471		$	1,298,310		$	6,504,824
Payroll and consulting fees		447,195			385,646			2,368,728
Costs for registration of patents		106,687			110,811			558,297
Compensation costs in respect of options granted to employees, directors and consultants		346,961			98,688			3,268,842
Other		338,635			160,350			886,242
Less - grants from the OCS and Bio Jerusalem Fund		(309,155	)		(372,959	)		(1,782,445	)
	$	2,271,794		$	1,680,845		$	11,804,488

GENERAL AND ADMINISTRATIVE EXPENSES (Tables)

12 Months Ended

Aug. 31, 2013

GENERAL AND ADMINISTRATIVE EXPENSES [Abstract]

Schedule of General and Administrative Expenses

					Period from April
						12, 2002
						(inception)
	Year ended					through
	August 31					August 31,
	2013		2012			2013

Compensation costs in respect of options granted to employees, directors and consultants	$	372,258	$	172,470		$	2,421,664
Professional services		439,175		221,218			2,338,919
Consulting fees		259,670		159,136			1,230,570
Travel costs		127,196		71,529			673,126
Write off of debt		-		-			275,000
Business development		308,183		284,899			1,124,128
Payroll and related expenses		230,191		144,101			983,399
Insurance		43,399		22,375			162,320
Other		252,057		127,436			984,550
	$	2,032,129	$	1,203,164		$	10,193,676

FINANCIAL INCOME AND EXPENSES (Tables)

12 Months Ended

Aug. 31, 2013

FINANCIAL INCOME AND EXPENSES [Abstract]

Schedule of Financial Income

	Year ended August 31
	2013		2012
Gain on sale of marketable securities (note 3)	$	90,370	$	-
Changes in fair value of warrants		44,699		-
Income from interest		18,728		13,126
Other		26,698		-
	$	180,495	$	13,126

Schedule of Financial Expenses

	Year ended August 31
	2013		2012
Exchange of warrants	$	296,982	$	-
Changes in fair value of warrants		-		142,704
Exchange rate differences		2,804		35,067
Bank commissions		13,660		14,952
Other		-		6,400
	$	313,446	$	199,123

TAXES ON INCOME (Tables)

12 Months Ended

Aug. 31, 2013

TAXES ON INCOME [Abstract]

Schedule of Deferred Income Taxes

	August 31
	2013			2012
In respect of:
Net operating loss carryforward		3,992,737			3,190,152
Research and development expenses		338,908			18,008
Less - Valuation allowance		(4,331,645	)		(3,208,160	)
Net deferred tax assets		-,-			-,-

Schedule of Income Taxes Included in the Income Statements

						Period from April
							12, 2002
							(inception)
	Year ended						through
	August 31						August 31,
	2013			2012			2013
Loss before taxes on income:
U.S.		1,185,831			599,067			9,626,374
Outside U.S.		3,251,044			2,655,193			12,461,502
	$	4,436,874		$	3,254,260		$	22,087,875
Income tax expenses (benefit):
Current:
U.S.		(12,960	)		(7,569	)		67,392
Outside U.S.		(192,102	)		97,787			108,440
	$	(205,062	)	$	90,218		$	175,832

Schedule of Reconciliation of Income Taxes

							Period from April
							12, 2002
							(inception)
	Year ended						through
	August 31						August 31,
	2013			2012			2013
Loss before income taxes as reported in
the consolidated statement of operations	$	(4,436,874	)	$	(3,254,260	)	$	(22,087,875	)
Statutory tax benefit		(1,522,906	)		(1,138,991	)		(7,700,757	)
Increase (decrease) in income taxes
resulting from:
Change in the balance of the valuation
allowance for deferred tax		902,509			516,749			3,573,334
Disallowable deductions		374,059			120,156			2,617,605
Increase in taxes resulting from
different tax rates applicable to the
Subsidiary		276,338			502,086			1,588,322
Uncertain tax position		(205,062	)		90,218			23,210
Taxes on income for the reported year	$	(205,062	)	$	90,218		$	35,714

Schedule of Unrecognized Tax Benefits Activity

	Year ended August 31
	2013			2012
Balance at Beginning of Year	$	228,272		$	138,054
Increase (decrease) in uncertain tax positions for the current year		(205,062	)		90,218
Balance at End of Year	$	23,210		$	228,272

RELATED PARTIES - TRANSACTIONS (Tables)

12 Months Ended

Aug. 31, 2013

Schedule of Balances with Related Parties

	August 31
	2013		2012
Accounts Receivable - KNRY	$	1,377	$	404
Accounts Receivable - Nadav Kidron*	$	3,153		-
Accounts payable and accrued expenses - KNRY	$	64,355		-

Schedule of Related Party Expenses

	August 31
	2013		2012
KNRY	$	448,080	$	318,271

SIGNIFICANT ACCOUNTING POLICIES (Details)	1 Months Ended	12 Months Ended			137 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details)	Oct. 31, 2012 USD ($)	Aug. 31, 2013 USD ($) shares	Aug. 31, 2013 ILS (₪) shares	Aug. 31, 2012 USD ($) shares	Aug. 31, 2013 USD ($) shares
SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Reverse stock split ratio		12			12
Common stock, shares issued, prior to reverse stock split		86,500,000			86,500,000
Common stock, shares outstanding, prior to reverse stock split		86,500,000			86,500,000
Common stock, shares authorized, prior to reverse stock split		200,000,000			200,000,000
Common stock, shares issued \| $		$ 95,238		$ 80,075	$ 95,238
Common stock, shares outstanding		7,937,872		6,674,068	7,937,872
Common stock, shares authorized		16,666,667		16,666,667	16,666,667
Related Party Transaction [Line Items]
Proceeds from issuance of common stock and warrants - net of issuance expenses \| $		$ 5,714,918		$ 3,488,942	$ 20,859,553
Fair value measurement
Restricted deposit \| $		16,000			16,000
D.N.A. Biomedical Solutions Ltd. [Member]
Related Party Transaction [Line Items]
Cost method investment \| $		1,027			$ 1,027
Proceeds from issuance of common stock and warrants - net of issuance expenses	$ 628,630	$ 114,130	₪ 420,000
Percent shares owned by investor		3.00%			3.00%
Percentage of D.N.A. shares owned		11.10%			11.10%
Computers and Peripheral Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation rate		33.00%			33.00%
Office Furniture and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Depreciation rate		15.00%			15.00%
Office Furniture and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Depreciation rate		33.00%			33.00%
Stock Options And Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		2,343,972	2,343,972	1,892,180

SHORT TERM INVESTMENTS (Details) - USD ($)	Aug. 31, 2013	Aug. 31, 2012
Short Term Investments [Line Items]
Amount	$ 5,246,627	$ 454,831
Dollars deposits [Member]
Short Term Investments [Line Items]
Interest rate		0.85%
Amount	$ 5,111,914	$ 260,371
Dollars deposits [Member] \| Minimum [Member]
Short Term Investments [Line Items]
Interest rate	0.60%
Dollars deposits [Member] \| Maximum [Member]
Short Term Investments [Line Items]
Interest rate	1.06%
NIS deposits [Member]
Short Term Investments [Line Items]
Interest rate	1.93%
Amount	$ 134,713	$ 194,010
NIS deposits [Member] \| Minimum [Member]
Short Term Investments [Line Items]
Interest rate		1.93%
NIS deposits [Member] \| Maximum [Member]
Short Term Investments [Line Items]
Interest rate		1.97%

MARKETABLE SECURITIES (Details)			1 Months Ended		12 Months Ended
MARKETABLE SECURITIES (Details)	Mar. 05, 2013 USD ($) shares	Mar. 05, 2013 ILS (₪) shares	Feb. 14, 2013 USD ($) shares	Feb. 14, 2013 ILS (₪) shares	Aug. 31, 2013 USD ($)	Aug. 31, 2012 USD ($)	Oct. 31, 2012 shares
MARKETABLE SECURITIES [Abstract]
Carrying value at the beginning of the period						$ 384,565
Additions - see note 9d					628,630
Changes in fair value					328,950
Reclassification adjustment for gains included in net loss					(52,343)
Reclassification to level 1					(905,237)	(384,565)
Carrying value at the end of the period
D.N.A. Biomedical Solutions Ltd. [Member]
Related Party Transaction [Line Items]
Option to purchase shares of D.N.A. \| shares							21,637,611
Shares of stock sold \| shares	1,750,000	1,750,000	3,500,000	3,500,000
Value of shares of stock sold	$ 112,540	₪ 420,000	$ 114,130	₪ 420,000
Percentage of D.N.A. shares owned					11.10%
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities					$ 956,376	$ 200,311

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)	Aug. 31, 2013	Aug. 31, 2012
PREPAID EXPENSES AND OTHER CURRENT ASSETS [Abstract]
Tax Authorities	$ 59,898	$ 53,341
Prepaid expenses and other receivables	30,205	36,657
Total prepaid expenses and other current assets	$ 90,103	$ 89,998

PROPERTY AND EQUIPMENT, NET (Details) - USD ($)	12 Months Ended		137 Months Ended
PROPERTY AND EQUIPMENT, NET (Details) - USD ($)	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
Property, Plant and Equipment [Line Items]
Cost	$ 130,271	$ 125,612	$ 130,271
Less - accumulated depreciation and amortization	124,503	120,844	124,503
Property and equipment, net	5,768	4,768	5,768
Depreciation expenses	5,379	14,737	126,223
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Cost	76,029	76,029	76,029
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	19,941	19,941	19,941
Computers and Peripheral Equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	$ 34,301	$ 29,642	$ 34,301

WARRANTS (Details)	1 Months Ended				3 Months Ended	12 Months Ended
WARRANTS (Details)	Nov. 30, 2012 USD ($) $ / pure shares	Nov. 29, 2012 USD ($) $ / pure shares	Aug. 31, 2012 USD ($) $ / pure shares	Jan. 31, 2011 $ / pure shares	Nov. 30, 2012 USD ($) $ / pure shares	Aug. 31, 2013 USD ($)	Aug. 31, 2012 USD ($) $ / pure shares	Oct. 31, 2012 $ / pure shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants			$ 637,182				$ 637,182
Warrants [Line Items]
Warrants (notes 6)			637,182				$ 637,182
Expected dividend yield (%)						0.00%	0.00%
Carrying value at the beginning of the period					$ 637,182	$ 637,182
Additional warrant liabilities granted						28,344	494,478
Changes in fair value						(44,699)	142,704
Exchange of warrants						(620,827)
Carrying value at the end of the period			$ 637,182				$ 637,182
2011 Warrants [Member]
Warrants [Line Items]
Number of shares authorized by warrant \| shares			246,341				246,341	290,459
Exercise price per share			4.44				4.44	3.7656
Three Warrants [Member]
Warrants [Line Items]
Number of warrants granted \| shares	16,892		112,613	182,292	137,311
Warrant term	5 years		5 years	5 years
Exercise price per share	6.00	3.7656	6.00	6.00	6.00		6.00
Financial expense					$ 296,982
New Warrant [Member]
Warrants [Line Items]
Number of warrants granted \| shares		137,311
Warrant term		4 years
Exercise price per share		7.20
Warrants (notes 6)		$ 145,173
Expected dividend yield (%)		0.00%
Expected option life (years)		4 years
Expected volatility		62.29%
Risk-free interest rate		0.57%
Kidron Option [Member]
Warrants [Line Items]
Number of shares authorized by warrant \| shares	112,690				112,690
Warrants (notes 6)	$ 168,220				$ 168,220
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants			$ 637,182				$ 637,182

EMPLOYEES RIGHTS UPON RETIREMENT (Details) - USD ($)	12 Months Ended
EMPLOYEES RIGHTS UPON RETIREMENT (Details) - USD ($)	Aug. 31, 2013	Aug. 31, 2012
EMPLOYEE RIGHTS UPON TERMINATION [Abstract]
Severance pay insurance deposits	$ 2,090	$ 3,620
Severance pay expenses	23,331	5,615
Severance pay expenses in respect of Contribution Plan	12,592	$ 7,089
Severance pay expected deposit	25,480
Severance pay expected liability to Contribution Plan	$ 22,835

COMMITMENTS (Details)	12 Months Ended			137 Months Ended
COMMITMENTS (Details)	Aug. 31, 2013 USD ($) $ / pure shares	Aug. 31, 2012 USD ($) $ / pure shares	Aug. 31, 2011 USD ($) $ / pure shares	Aug. 31, 2013 USD ($) $ / pure shares	Nov. 04, 2013 shares	Aug. 31, 2013 ILS (₪) $ / pure shares	Apr. 15, 2013 shares
Related Party Transaction [Line Items]
Professional services	$ 439,175	$ 221,218		$ 2,338,919
Expected dividend yield (%)	0.00%	0.00%
Research and development expenses	$ 2,271,794	$ 1,680,845		11,804,488
Minimum [Member]
Related Party Transaction [Line Items]
Expected option life (years)	5 years 9 months	5 years 6 months
Maximum [Member]
Related Party Transaction [Line Items]
Expected option life (years)	6 years	5 years 9 months
Hadasit [Member]
Related Party Transaction [Line Items]
Commitments for consulting services	$ 200,000
Professional services	50,000
Consultant [Member]
Related Party Transaction [Line Items]
Commitments for consulting service, monthly fixed fee	$ 8,000			$ 8,000
Royalty percentage	8.00%			8.00%		8.00%
Number of shares authorized by warrant \| shares	20,834			20,834		20,834
Exercise price per share	6.00			6.00		6.00
Warrants vesting, number of installments	5			5		5
Fair value of options granted	$ 62,185			$ 62,185
Expected dividend yield (%)	0.00%		0.00%
Expected volatility	76.87%		78.65%
Risk-free interest rate	2.33%		3.62%
Expected option life (years)	7 years 5 months 16 days		10 years
Third Party [Member]
Related Party Transaction [Line Items]
Number of shares authorized by warrant \| shares			32,000
Warrant term			5 years
Exercise price per share			6.00
Warrants vesting, number of installments			12
Fair value of options granted	$ 9,169		$ 5,057	9,169
Expected dividend yield (%)	0.00%		0.00%
Expected volatility	76.41%		77.39%
Risk-free interest rate	0.79%		1.55%
Expected option life (years)	2 years 10 months 24 days		5 years
Related Party [Member]
Related Party Transaction [Line Items]
Shares to be issued for services \| shares		25,000
Number of shares authorized by warrant \| shares		62,500
Warrant term		5 years
Exercise price per share		6.00
Warrants vesting, number of installments		12
Fair value of options granted	$ 164,752	$ 121,304		$ 164,752
Expected dividend yield (%)	0.00%	0.00%
Expected volatility	76.16%	76.82%
Risk-free interest rate	0.77%	0.81%
Expected option life (years)	4 years	5 years
Advisor [Member]
Related Party Transaction [Line Items]
Shares to be issued for services \| shares	5,000			5,000	10,000	5,000	15,000
Warrants vesting, number of installments							3
Fair value of options granted	$ 34,900			$ 34,900
Clinical Research Organization [Member]
Related Party Transaction [Line Items]
Commitments for consulting services	332,702
Professional services	89,830
Master Service Agreement [Member]
Related Party Transaction [Line Items]
Commitments for consulting services	102,280
Professional services	$ 30,684
Bio-Jerusalem [Member]
Related Party Transaction [Line Items]
Royalty percentage	4.00%			4.00%		4.00%
Royalty percentage, maximum percentage of grants received	100.00%			100.00%		100.00%
Capital raise amount	$ 65,053			$ 65,053
Research and development expenses	$ 12,319			$ 65,053
Chief Scientist Office [Member]
Related Party Transaction [Line Items]
Royalty percentage, maximum percentage of grants received	100.00%			100.00%		100.00%
Capital raise amount	$ 1,659,338			$ 1,659,338
Research and development expenses	$ 296,836	$ 372,959		$ 1,717,392
Chief Scientist Office [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Royalty percentage	3.00%			3.00%		3.00%
Chief Scientist Office [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Royalty percentage	3.50%			3.50%		3.50%
Vehicles Lease [Member]
Long-term Purchase Commitment [Line Items]
Operating lease term	3 years
Lease expenses	$ 29,603	$ 29,543
Future lease payments due in 2014	24,603			$ 24,603
Future lease payments due in 2015	17,615			17,615
Future lease payments due in 2016	7,340			7,340
Deposit for lease agreement	$ 1,959
Office Facilities Lease [Member]
Long-term Purchase Commitment [Line Items]
Operating lease term	36 months	57 months
Lease expenses	$ 13,116	$ 9,132
Future lease payments due in 2014	$ 24,641			$ 24,641		₪ 89,052

STOCKHOLDERS' EQUITY (Details)					1 Months Ended			3 Months Ended	12 Months Ended							65 Months Ended	137 Months Ended
STOCKHOLDERS' EQUITY (Details)	Jul. 05, 2012 USD ($) shares	May 15, 2012 USD ($) shares	Mar. 14, 2012 USD ($) shares	Dec. 12, 2011 USD ($) shares	Jul. 30, 2013 USD ($) $ / shares shares	Oct. 31, 2012 USD ($) shares	Aug. 31, 2012 USD ($) $ / shares $ / pure shares	Nov. 30, 2012 USD ($) $ / shares $ / pure shares	Aug. 31, 2013 USD ($)	Aug. 31, 2013 ILS (₪)	Aug. 31, 2012 USD ($) $ / pure shares	Aug. 31, 2011 USD ($)	Aug. 31, 2010 USD ($)	Aug. 31, 2009 USD ($)	Aug. 31, 2008 USD ($)	Aug. 31, 2007 USD ($)	Aug. 31, 2013 USD ($)
Related Party Transaction [Line Items]
Proceeds from issuance of shares \| $									$ 5,714,918		$ 3,488,942						$ 20,859,553
Stock issued for services, shares					12,042
Stock issued for services \| $					$ 86,221						$ 107,860	$ 227,569	$ 249,850	$ 152,928	$ 116,110	$ 98,750
Advisor [Member]
Related Party Transaction [Line Items]
Stock issued for services, shares		6,917	6,917	6,917
Stock issued for services \| $		$ 24,900	$ 26,560	$ 24,900
Advisor Two [Member]
Related Party Transaction [Line Items]
Stock issued for services, shares	4,167		4,167		16,667
Stock issued for services \| $	$ 16,000		$ 15,500		$ 123,336
Securities Purchase Agreement [Member]
Related Party Transaction [Line Items]
Securities Purchase Agreements, number of units							801,942	335,524
Securities Purchase Agreements, purchase price per unit \| $ / shares							$ 4.44	$ 4.44
Proceeds from issuance of shares \| $							$ 3,560,192	$ 1,464,425
Securities Purchase Agreements, number of shares per unit							1	1
Securities Purchase Agreements, number of warrants per unit							1	1
Securities Purchase Agreements, number of shares per warrant							0.50	0.50
Warrant term							5 years	5 years
Exercise price per share							6.00	6.00			6.00
Securities Purchase Agreement Two [Member]
Related Party Transaction [Line Items]
Securities Purchase Agreements, number of units					658,144		5,652
Number of shares to be sold							5,625				5,625
Number of shares authorized by warrant							2,826				2,826
Securities Purchase Agreements, purchase price per unit \| $ / shares					$ 7.00		$ 4.44
Proceeds from issuance of shares \| $					$ 4,238,889		$ 25,093
Securities Purchase Agreements, number of shares per unit							1
Securities Purchase Agreements, number of warrants per unit							1
Securities Purchase Agreements, number of shares per warrant							0.50
Warrant term							5 years
Exercise price per share							6.00				6.00
Finders fee \| $					$ 255,246		$ 71,250
Leading Investor [Member]
Related Party Transaction [Line Items]
Securities Purchase Agreements, number of units							225,226	33,784
Percent shares owned by investor							5.00%	5.00%			5.00%
Other Individual [Member]
Related Party Transaction [Line Items]
Number of shares to be sold								1,127
Number of shares authorized by warrant								564
Finders fee \| $								$ 12,885
Directors [Member]
Related Party Transaction [Line Items]
Number of shares to be sold								12,745
Number of shares authorized by warrant								6,373
D.N.A. Biomedical Solutions Ltd. [Member]
Related Party Transaction [Line Items]
Number of shares to be sold						199,172
Proceeds from issuance of shares						$ 628,630			$ 114,130	₪ 420,000
Warrant term												5 years
Option to purchase shares of D.N.A.						21,637,611
Percent shares owned by investor									3.00%	3.00%							3.00%

STOCKBASED COMPENSATION (Narrative) (Details)	1 Months Ended	12 Months Ended						65 Months Ended	137 Months Ended
STOCKBASED COMPENSATION (Narrative) (Details)	Jul. 30, 2013 USD ($) shares	Aug. 31, 2013 USD ($) $ / shares shares	Aug. 31, 2012 USD ($) $ / shares shares	Aug. 31, 2011 USD ($)	Aug. 31, 2010 USD ($)	Aug. 31, 2009 USD ($)	Aug. 31, 2008 USD ($)	Aug. 31, 2007 USD ($)	Aug. 31, 2013 USD ($) shares	Nov. 30, 2012 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued for services, shares	12,042
Stock issued for services \| $	$ 86,221		$ 107,860	$ 227,569	$ 249,850	$ 152,928	$ 116,110	$ 98,750
Proceeds from issuance of shares \| $		$ 5,714,918	$ 3,488,942						$ 20,859,553
Expected dividend yield (%)		0.00%	0.00%
Expected stock price volatility (%), minimum		64.35%	76.03%
Expected stock price volatility (%), maximum		75.46%
Risk-free interest rate (%), minimum		0.92%	0.83%
Risk-free interest rate (%), maximum		1.01%	1.0375%
Intrinsic value of options exercised \| $		$ 17,584
Nadav Kidron and Miriam Kidron [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted - at market price			144,000
Granted - at market price \| $ / shares			$ 4.08
Options vesting, number of installments			17
Options vested			42,000
Shares per installment			6,000
Fair value of options granted \| $			$ 373,565
Expected dividend yield (%)			0.00%
Expected volatility			76.03%
Risk-free interest rate			0.83%
Expected option life (years)			5 years 6 months
Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted - at market price		20,000	43,334
Granted - at market price \| $ / shares		$ 6.00	$ 4.08
Options to purchase, number of shares										6,373
Options vesting, number of installments		2	2						2
Fair value of options granted \| $		$ 41,402	$ 114,694						$ 41,402
Expected dividend yield (%)		0.00%	0.00%
Expected volatility		64.35%	76.03%
Risk-free interest rate		1.01%	1.0375%
Expected option life (years)		5 years 9 months	5 years 9 months
Subsidiary Employee One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted - at market price		4,667	50,750
Granted - at market price \| $ / shares		$ 6.00	$ 4.08
Options vesting, number of installments		2	29						2
Fair value of options granted \| $		$ 9,660	$ 134,324						$ 9,660
Expected dividend yield (%)		0.00%	0.00%
Expected volatility		64.35%	76.03%
Risk-free interest rate		1.01%	1.0375%
Expected option life (years)		5 years 9 months	5 years 9 months
Subsidiary Employee Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted - at market price		100,800	6,250
Granted - at market price \| $ / shares		$ 7.88	$ 4.08
Options vesting, number of installments		35	3						35
Shares per installment		1,400
Fair value of options granted \| $		$ 519,785	$ 16,780						$ 519,785
Expected dividend yield (%)		0.00%	0.00%
Expected volatility		75.46%	76.03%
Risk-free interest rate		0.92%	0.935%
Expected option life (years)		6 years	6 years
Miriam Kidron [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted - at market price			280,114
2008 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares reserved for grant		1,000,000							1,000,000

STOCKBASED COMPENSATION (Schedule of Fair Value Assumptions) (Details)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility (%), minimum	64.35%	76.03%
Expected stock price volatility (%), maximum	75.46%
Risk-free interest rate (%), minimum	0.92%	0.83%
Risk-free interest rate (%), maximum	1.01%	1.0375%
Expected dividend yield (%)	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option life (years)	5 years 9 months	5 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option life (years)	6 years	5 years 9 months

STOCKBASED COMPENSATION (Schedule of Stock Option Activity) (Details) - USD ($)	12 Months Ended		137 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
Weighted average exercise price
Stockbased compensation expense	$ 372,258	$ 172,470	$ 2,421,664
Employees [Member]
Number of options
Options outstanding at beginning of year	932,116	834,117
Granted - at market price	100,800	244,334
Granted - above market price	24,667
Expired		(141,667)
Forfeited		(4,667)
Exercised	(8,334)
Options outstanding at end of year	1,049,249	932,116	1,049,249
Options exercisable at end of year	870,833	717,088	870,833
Weighted average fair value of options granted during the year	$ 4.55	$ 2.65
Weighted average exercise price
Options outstanding at beginning of year	3.72	3.84
Granted - at market price	7.88	4.08
Granted - above market price	6.00
Expired		5.40
Forfeited		5.64
Exercised	5.04
Options outstanding at end of year	$ 4.13	$ 3.72	$ 4.13
Stockbased compensation expense	$ 562,966	$ 200,866
Unrecognized compensation expense	$ 475,485		$ 475,485
Period over which compensation expense will be recognized	32 months
Nonemployees [Member]
Number of options
Options outstanding at beginning of year	144,856	82,356
Granted - above market price		62,500
Options outstanding at end of year	144,856	144,856	144,856
Options exercisable at end of year	109,969	88,689	109,969
Weighted average exercise price
Options outstanding at beginning of year	$ 6.66	$ 7.20
Granted - above market price		6.00
Options outstanding at end of year	$ 6.66	$ 6.66	$ 6.66
Stockbased compensation expense	$ 156,253	$ 117,098
Unrecognized compensation expense	$ 52,949		$ 52,949
Period over which compensation expense will be recognized	33 months

STOCKBASED COMPENSATION (Summary of Information for Options Outstanding and Exercisable by Exercise Price Range) (Details)	12 Months Ended
	Aug. 31, 2013 USD ($) $ / shares shares
Employees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding \| shares	1,049,249
Outstanding, weighted average remaining contractual life, years	5 years 7 months 28 days
Outstanding, weighted average exercise price \| $ / shares	$ 4.13
Outstanding, aggregate intrinsic value \| $	$ 3,379,544
Number exercisable \| shares	870,883
Exercisable, weighted average remaining contractual life, years	4 years 11 months 1 day
Exercisable, weighted average exercise price \| $ / shares	$ 3.72
Exercisable, aggregate intrinsic value \| $	$ 3,113,790
Nonemployees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding \| shares	144,856
Outstanding, weighted average remaining contractual life, years	3 years 11 months 1 day
Outstanding, weighted average exercise price \| $ / shares	$ 6.66
Outstanding, aggregate intrinsic value \| $	$ 151,785
Number exercisable \| shares	109,969
Exercisable, weighted average remaining contractual life, years	3 years 6 months 18 days
Exercisable, weighted average exercise price \| $ / shares	$ 6.40
Exercisable, aggregate intrinsic value \| $	$ 128,283
$0.012 [Member] \| Employees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding \| shares	280,114
Outstanding, weighted average remaining contractual life, years	11 months 5 days
Outstanding, weighted average exercise price \| $ / shares	$ 0.012
Outstanding, aggregate intrinsic value \| $	$ 2,038,670
Number exercisable \| shares	290,114
Exercisable, weighted average remaining contractual life, years	11 months 5 days
Exercisable, weighted average exercise price \| $ / shares	$ 0.012
Exercisable, aggregate intrinsic value \| $	$ 2,038,670
$4.08 to 6.00 [Member] \| Employees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding \| shares	668,335
Outstanding, weighted average remaining contractual life, years	7 years 18 days
Outstanding, weighted average exercise price \| $ / shares	$ 5.28
Outstanding, aggregate intrinsic value \| $	$ 1,340,874
Number exercisable \| shares	578,169
Exercisable, weighted average remaining contractual life, years	6 years 8 months 27 days
Exercisable, weighted average exercise price \| $ / shares	$ 5.43
Exercisable, aggregate intrinsic value \| $	$ 1,075,120
$4.08 to 6.00 [Member] \| Nonemployees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding \| shares	111,520
Outstanding, weighted average remaining contractual life, years	3 years 9 months 15 days
Outstanding, weighted average exercise price \| $ / shares	$ 5.93
Outstanding, aggregate intrinsic value \| $	$ 151,785
Number exercisable \| shares	93,301
Exercisable, weighted average remaining contractual life, years	3 years 5 months 1 day
Exercisable, weighted average exercise price \| $ / shares	$ 5.92
Exercisable, aggregate intrinsic value \| $	$ 128,283
$7.88 to 9.12 [Member] \| Employees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding \| shares	100,800
Outstanding, weighted average remaining contractual life, years	9 years 7 months 13 days
Outstanding, weighted average exercise price \| $ / shares	$ 7.88
Outstanding, aggregate intrinsic value \| $
Number exercisable \| shares	12,600
Exercisable, weighted average remaining contractual life, years	9 years 7 months 13 days
Exercisable, weighted average exercise price \| $ / shares	$ 7.88
Exercisable, aggregate intrinsic value \| $
$7.88 to 9.12 [Member] \| Nonemployees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding \| shares	33,336
Outstanding, weighted average remaining contractual life, years	4 years 3 months 29 days
Outstanding, weighted average exercise price \| $ / shares	$ 9.12
Outstanding, aggregate intrinsic value \| $
Number exercisable \| shares	16,668
Exercisable, weighted average remaining contractual life, years	4 years 3 months 29 days
Exercisable, weighted average exercise price \| $ / shares	$ 9.12
Exercisable, aggregate intrinsic value \| $

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($)	Aug. 31, 2013	Aug. 31, 2012
ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]
Service providers	$ 392,289	$ 580,714
Payroll and related expenses	58,652	16,459
Accounts payable and accrued expenses	$ 450,941	$ 597,173

RESEARCH AND DEVELOPMENT EXPENSES, NET (Details) - USD ($)	12 Months Ended		137 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
RESEARCH AND DEVELOPMENT EXPENSES, NET [Abstract]
Clinical trials	$ 1,341,471	$ 1,298,310	$ 6,504,824
Payroll and consulting fees	447,195	385,646	2,368,728
Costs for registration of patents	106,687	110,811	558,297
Compensation costs in respect of options granted to employees, directors and consultants	346,961	98,688	3,268,842
Other	338,635	160,350	886,242
Less - grants from the OCS	(309,155)	(372,959)	1,782,445
Research and Development Expense	$ 2,271,794	$ 1,680,845	$ 11,804,488

GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($)	12 Months Ended		137 Months Ended
GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($)	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
GENERAL AND ADMINISTRATIVE EXPENSES [Abstract]
Stockbased compensation expense	$ 372,258	$ 172,470	$ 2,421,664
Professional services	439,175	221,218	2,338,919
Consulting fees	259,670	159,136	1,230,570
Travel costs	127,196	71,529	673,126
Write off of debt			275,000
Business development	308,183	284,899	1,124,128
Payroll and related expenses	230,191	144,101	983,399
Insurance	43,399	22,375	162,320
Other	252,057	127,436	984,550
General and Administrative Expense	$ 2,032,129	$ 1,203,164	$ 10,193,676

FINANCIAL INCOME AND EXPENSES (Details) - USD ($)	12 Months Ended		137 Months Ended
FINANCIAL INCOME AND EXPENSES (Details) - USD ($)	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
Financial income
Gain on sale of marketable securities (note 3)	$ 90,370
Changes in fair value of warrant liabilities	44,699
Income from interest	18,728	13,126
Other	26,698
Financial income	180,495	13,126	$ 387,653
Financial expenses
Exchange of warrants	296,982		296,982
Changes in fair value of warrant liabilities		142,704
Exchange rate differences	2,804	35,067
Bank commissions	13,660	14,952
Other		6,400
Financial expenses	$ 313,446	$ 199,123	$ 693,826

TAXES ON INCOME (Narrative) (Details) - USD ($)	12 Months Ended
TAXES ON INCOME (Narrative) (Details) - USD ($)	Aug. 31, 2013	Aug. 31, 2012
Taxes On Income [Line Items]
Corporate tax rate	35.00%
Net operating loss carryforwards	$ 5,605,237	$ 4,896,605
Penalties related to tax contingencies	$ 0	15,539
Subsidiary [Member]
Taxes On Income [Line Items]
Corporate tax rate	25.00%
Net operating loss carryforwards	$ 7,663,790	$ 5,905,361

TAXES ON INCOME (Schedule of Deferred Income Taxes) (Details) - USD ($)	Aug. 31, 2013	Aug. 31, 2012
TAXES ON INCOME [Abstract]
Net operating loss carryforward	$ 3,992,737	$ 3,190,152
Research and development expenses	338,908	18,008
Less - Valuation allowance	(4,331,645)	(3,208,160)
Net deferred tax assets

TAXES ON INCOME (Schedule of Income Taxes Included in the Income Statements) (Details) - USD ($)	12 Months Ended		137 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
TAXES ON INCOME [Abstract]
U.S.	$ 1,185,831	$ 599,067	$ 9,626,374
Outside U.S.	3,251,044	2,655,193	12,461,502
Loss before taxes on income	4,436,874	3,254,260	22,087,875
U.S.	(12,960)	(7,569)	67,392
Outside U.S.	(192,102)	97,787	108,440
Taxes on income	$ (205,062)	$ 90,218	$ 35,714

TAXES ON INCOME (Schedule of Reconciliation of Income Taxes) (Details) - USD ($)	12 Months Ended		137 Months Ended
	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
TAXES ON INCOME [Abstract]
Loss before income taxes as reported in the consolidated statement of operations	$ (4,436,874)	$ (3,254,260)	$ (22,087,875)
Statutory tax benefit	(1,522,906)	(1,138,991)	(7,700,757)
Change in the balance of the valuation allowance for deferred tax losses	902,509	516,749	3,573,334
Disallowable deductions	374,059	120,156	2,617,605
Increase in taxes resulting from different tax rates applicable to non U.S. subsidiary	276,338	502,086	1,588,322
Uncertain tax position	(205,062)	90,218	23,210
Taxes on income	$ (205,062)	$ 90,218	$ 35,714

TAXES ON INCOME (Schedule of Unrecognized Tax Benefits) (Details) - USD ($)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
TAXES ON INCOME [Abstract]
Balance at Beginning of Year	$ 228,272	$ 138,054
Increase (decrease) in tax positions for prior years	(205,062)	90,218
Balance at End of Year	$ 23,210	$ 228,272

RELATED PARTIES - TRANSACTIONS (Narrative) (Details) - USD ($)	12 Months Ended
	Aug. 31, 2013	Aug. 31, 2012
Directors [Member]
Related Party Transaction [Line Items]
Amount of transaction	$ 39,361	$ 30,000
JV Agreement [Member]
Related Party Transaction [Line Items]
Salary	250,000
Car and cash bonus	60,000
Nadav Kidron [Member]
Related Party Transaction [Line Items]
Salary	200,000
Car and cash bonus	$ 20,000

RELATED PARTIES - TRANSACTIONS (Schedule of Balances with Related Parties) (Details) - USD ($)

12 Months Ended

Aug. 31, 2013

Aug. 31, 2012

Accounts Receivable

$ 4,530

$ 404

Nadav Kidron [Member]

Accounts Receivable

3,153

^[1]

KNRY [Member]

Accounts Receivable

1,377

404

Accounts payable and accrued expenses

64,355

Expenses to related parties

$ 448,080

$ 318,271

[1]	Down payment for travel expenses.

SUBSEQUENT EVENTS (Details) - USD ($)	2 Months Ended	12 Months Ended		137 Months Ended
SUBSEQUENT EVENTS (Details) - USD ($)	Nov. 25, 2013	Aug. 31, 2013	Aug. 31, 2012	Aug. 31, 2013
Subsequent Event [Line Items]
Common stock issued for services		$ 244,457	$ 107,860	$ 1,400,413
Subsidiary [Member]
Subsequent Event [Line Items]
Shares of stock sold	1,025,991
Value of shares of stock sold	$ 43,208
Percentage of D.N.A. shares owned	10.60%
Advisor [Member]
Subsequent Event [Line Items]
Common stock issued for services	$ 10,000

Label	Element	Value
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 2,122,981
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants	ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	177,782
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1,968,547
Adjustment To Additional Paid In Capital Imputed Interest	ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest	8,437
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	108,000
Adjustments to Additional Paid in Capital, Other	us-gaap_AdjustmentsToAdditionalPaidInCapitalOther	18,991
Stock Issued During Period, Value, Purchase of Assets	us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets	434,876
Deficit accumulated during the development stage [Member]
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss	(4,478,917)
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants	ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
Adjustment To Additional Paid In Capital Imputed Interest	ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
Adjustments to Additional Paid in Capital, Other	us-gaap_AdjustmentsToAdditionalPaidInCapitalOther
Stock Issued During Period, Value, Purchase of Assets	us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets
Stock Issued During Period Value Services	ormp_StockIssuedDuringPeriodValueServices
Additional paid-in capital [Member]
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	2,095,800
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants	ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	177,782
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1,968,547
Adjustment To Additional Paid In Capital Imputed Interest	ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest	8,437
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	108,000
Adjustments to Additional Paid in Capital, Other	us-gaap_AdjustmentsToAdditionalPaidInCapitalOther	18,991
Stock Issued During Period, Value, Purchase of Assets	us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets	433,732
Stock Issued During Period Value Services	ormp_StockIssuedDuringPeriodValueServices	98,625
Comprehensive Income [Member]
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants	ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
Adjustment To Additional Paid In Capital Imputed Interest	ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
Adjustments to Additional Paid in Capital, Other	us-gaap_AdjustmentsToAdditionalPaidInCapitalOther
Stock Issued During Period, Value, Purchase of Assets	us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets
Stock Issued During Period Value Services	ormp_StockIssuedDuringPeriodValueServices
Common Stock [Member]
Net Income (Loss) Attributable to Parent	us-gaap_NetIncomeLoss
Shares Cancelled Value	ormp_SharesCancelledValue	19,800
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	27,181
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants	ormp_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants
Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition	us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
Stock Issued During Period Shares Services	ormp_StockIssuedDuringPeriodSharesServices	10,417
Stock Issued During Period, Shares, Purchase of Assets	us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets	95,368
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	2,265,514
Adjustment To Additional Paid In Capital Imputed Interest	ormp_AdjustmentToAdditionalPaidInCapitalImputedInterest
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
Adjustments to Additional Paid in Capital, Other	us-gaap_AdjustmentsToAdditionalPaidInCapitalOther
Stock Issued During Period, Value, Purchase of Assets	us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets	1,144
Stock Issued During Period Value Services	ormp_StockIssuedDuringPeriodValueServices	$ 125